Biomarkers and their uses
By analyzing SNPs in conserved rRNA genes, the method provides rapid and reliable identification of microorganisms, addressing the limitations of current diagnostic techniques and enabling timely infection management.
Patent Information
- Application Number
- JP2023087731
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-05-17
- Filing Date
- 2023-05-29
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2038-05-17
AI Technical Summary
Current diagnostic techniques for microorganisms, such as bacteria, yeast organisms, and filamentous fungi, are slow, lack sensitivity and specificity, and require extensive handling, which is undesirable for security-sensitive agents, and PCR methods lack confidence in culture results without clinical symptoms.
Utilizing the high conservation of 16S rRNA genes in bacteria and 18S rRNA genes in yeast and fungi, the method involves analyzing single nucleotide polymorphisms (SNPs) at specific positions in these genes to identify and classify microorganisms rapidly and accurately.
Enables rapid and reliable identification and classification of microorganisms, facilitating early treatment of infections and effective management of microbial populations, improving diagnostic accuracy and reducing handling risks.
Smart Images

Figure 0007586531000013 
Figure 0007586531000014 
Figure 0007586531000015
Abstract
Description
[Technical field]
[0001] The present invention generally relates to methods and agents for identifying and / or classifying microorganisms. The methods and agents are based on the detection of polymorphisms in the 16S ribosomal RNA gene or gene product in bacteria and in the 18S ribosomal RNA gene or gene product in yeast organisms and filamentous fungi. The invention also features methods for the treatment of bacterial, yeast organism or filamentous fungal infections based on the diagnostic methods of the invention. [Background technology]
[0002] Rapid and accurate identification or classification of microorganisms (such as bacteria), yeast organisms and filamentous fungi in a sample is highly desirable.
[0003] First, and most importantly, rapid and accurate diagnosis of such infections can mean the difference between life and death for a patient by enabling early administration of effective treatment or therapy.
[0004] Rapid and accurate identification or classification can aid in the implementation of effective control measures to manage, control, eradicate and / or eliminate microorganisms, yeast organisms or mold fungi in a contaminated solution, material or food that might otherwise pose a threat to the welfare of the organism or the production quality of the solution, material or food.
[0005] Furthermore, rapid and accurate identification or classification can aid in naturally occurring microbial, yeast organisms and filamentous fungal populations in a sample, for example for ecological studies of microbial diversity, phylum spectrum and / or relative phylum abundance, or for monitoring deviations of equilibrium from normal conditions in pathological conditions of organisms, such as intestinal, respiratory and skin disorders.
[0006] It may be desirable to quickly and accurately identify or classify microorganisms, yeasts or molds following therapy, treatment or modulation. For example, rapid microbial identification or classification may be beneficial in the analysis of antibiotics, steroids, immune modulators, pre- and post-use biomaterials, soil or water treatment, filtration, sterilization procedures and disinfectant use.
[0007] Currently, most commercially available diagnostic techniques generally require the isolation and identification of live microorganisms, yeast organisms and filamentous fungi from samples using culture, but this technique suffers from significant turnaround times and suboptimal sensitivity, specificity and predictive value. It may also require more extensive handling of the organism, which may be particularly undesirable for some organisms, such as security-sensitive biological agents.
[0008] Available alternative diagnostic techniques include the use of polymerase chain reaction (PCR), especially in conjunction with culture. A problem with such techniques, however, is the lack of confidence in culture results or in an initial positive PCR result in the absence of relevant clinical or physical symptoms. Another problem with such techniques, as with culture, is the lack of sensitivity and specificity when attempting to detect small amounts of microbial nucleic acid in a background of host nucleic acid. Summary of the Invention [Problem to be solved by the invention]
[0009] Thus, there is a recognized need for rapid and reliable techniques for accurate diagnosis of bacteria, yeast organisms and / or filamentous fungi. [Means for solving the problem]
[0010] In various aspects, the present invention is based in part on the high conservation of the 16S (Svedberg unit) ribosomal RNA (16S rRNA) gene among prokaryotes, including bacteria, and the high conservation of the 18S ribosomal RNA (18S rRNA) gene among yeast organisms and filamentous fungi, and further based in part on the discovery of multiple single nucleotide polymorphisms (SNPs) in the 16S rRNA gene and the 18S rRNA gene that can be beneficial in identifying and classifying microorganisms, particularly bacterial microorganisms, and yeast organisms and / or filamentous fungi, in a sample.
[0011] Generally speaking, prokaryotes, including bacteria, contain 16S rRNA, which is a component of the 30S small subunit of the prokaryotic ribosome. 16S rRNA is approximately 1,500 nucleotides in length and is encoded by the 16S rRNA gene (also called 16S rDNA), which is generally part of a cotranscribed operon that also contains the 23S and 5S rRNA genes. The DNA sequence of the 16S rRNA gene (and therefore the RNA sequence of the 16S rRNA molecule) is highly conserved among prokaryotes, although there are regions of variation (Weisberg WG, et al., 1991).
[0012] Similarly, the 18S rRNA gene of yeast and filamentous fungi is a homolog of the 16S rRNA gene of prokaryotes. 18S rRNA is a component of the 40S small eukaryotic ribosomal subunit. The DNA sequence of the 18S rRNA gene (and therefore the RNA sequence of the 18S rRNA molecule) is also highly conserved in yeast and filamentous fungi.
[0013] According to a first aspect of the present invention there is provided a method for identifying, partially identifying or classifying at least one bacterium, yeast organism or filamentous fungus in a sample. In one embodiment, the method comprises analyzing at least a portion of a bacterial 16S rRNA gene or gene product from a sample, or at least a portion of a yeast organism or filamentous fungal 18S rRNA gene or gene product from a sample for the presence or absence of at least one single nucleotide polymorphism (SNP); wherein at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, and 653 of the 16S rRNA gene set forth in SEQ ID NO:1; or At least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is in or corresponds to the 16S rRNA gene set forth in SEQ ID NO: 43; or At least one bacterium, yeast organism, or filamentous fungus in the sample is identified, partially identified, or classified based on the presence or absence of at least one SNP. In another embodiment, the method comprises analyzing at least a portion of a bacterial 16S rRNA gene or gene product from the sample, or at least a portion of a yeast organism or filamentous fungal 18S rRNA gene or gene product from the sample for the presence or absence of at least one single nucleotide polymorphism (SNP); wherein at least one SNP in at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of the 16S rRNA gene set forth in SEQ ID NO:1; At least one bacterium, yeast organism, or filamentous fungus in the sample is identified, partially identified, or classified based on the presence or absence of at least one SNP.
[0014] According to a second aspect of the invention there is provided a method of identifying, partially identifying, classifying or diagnosing a bacterial, yeast organism or filamentous fungal infection in a subject. In one embodiment, the method comprises analyzing for the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or a filamentous fungus in a sample from the subject; wherein at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653 of the 16S rRNA gene set forth in SEQ ID NO:1; or At least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is in or corresponds to the 16S rRNA gene set forth in SEQ ID NO: 43; or The presence or absence of at least one of said SNPs in at least a portion of the 16S rRNA gene or gene product, or at least a portion of the 18S rRNA gene or gene product, is used to identify, partially identify, classify or diagnose a bacterial, yeast organism or filamentous fungal infection in a subject. In another embodiment, the method comprises analyzing for the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or a filamentous fungus in a sample from the subject; wherein at least one SNP in at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of the 16S rRNA gene set forth in SEQ ID NO:1; The presence or absence of at least one of said SNPs in at least a portion of the 16S rRNA gene or gene product, or at least a portion of the 18S rRNA gene or gene product, is used to identify, partially identify, classify or diagnose a bacterial, yeast organism or filamentous fungal infection in a subject.
[0015] According to a third aspect of the invention there is provided a method of treating a subject having a bacterial, yeast organism or mould infection comprising the steps of: identifying, partially identifying, classifying or diagnosing a bacterial, yeast organism or fungal infection in a subject by the method of the second aspect to identify, partially identify, classify or diagnose a bacterial, yeast organism or fungal infection in a subject; administering to the subject a therapy or treatment for treating a bacterial, yeast organism, or mold infection in the subject; A method is provided that includes:
[0016] According to a fourth aspect of the invention there is provided at least one isolated probe, tool or reagent.
[0017] In one embodiment of the fourth aspect, the at least one isolated probe, tool or reagent is capable of identifying, partially identifying or classifying at least one bacterium, yeast organism or filamentous fungus in a sample, and the probe, tool or reagent is capable of binding, detecting or identifying the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus; wherein at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653 of the 16S rRNA gene set forth in SEQ ID NO:1; or At least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is in or corresponds to the 16S rRNA gene set forth in SEQ ID NO:43.
[0018] In another embodiment of the fourth aspect, the at least one isolated probe, tool or reagent is capable of identifying, partially identifying or classifying at least one bacterium, yeast organism or filamentous fungus in a sample, and the probe, tool or reagent is capable of binding, detecting or identifying the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus; wherein at least one SNP in at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762 and 776 of the 16S rRNA gene set forth in SEQ ID NO:1.
[0019] According to another embodiment of the fourth aspect, at least one isolated probe, tool or reagent is capable of distinguishing between a sample comprising at least one bacterium, yeast organism or filamentous fungus and a sample not comprising at least one bacterium, yeast organism or filamentous fungus, and the probe, tool or reagent is capable of binding, detecting or identifying the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus; wherein at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653 of the 16S rRNA gene set forth in SEQ ID NO:1; or At least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is in or corresponds to the 16S rRNA gene set forth in SEQ ID NO:43.
[0020] According to another embodiment of the fourth aspect, at least one isolated probe, tool or reagent is capable of distinguishing between a sample comprising at least one bacterium, yeast organism or filamentous fungus and a sample not comprising at least one bacterium, yeast organism or filamentous fungus, and the probe, tool or reagent is capable of binding, detecting or identifying the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus; wherein at least one SNP in at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762 and 776 of the 16S rRNA gene set forth in SEQ ID NO:1.
[0021] According to a fifth aspect of the invention there is provided a method for identifying, partially identifying or classifying at least one bacterium, yeast organism or filamentous fungus in a sample. In one embodiment, the method comprises: combining at least one isolated probe, tool or reagent of the fourth aspect with a sample; and identifying, partially identifying, or classifying at least one bacterium, yeast organism, or filamentous fungus based on the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of the yeast organism or filamentous fungus; wherein at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653 of the 16S rRNA gene set forth in SEQ ID NO:1; or At least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is in or corresponds to the 16S rRNA gene set forth in SEQ ID NO:43. In another embodiment, the method comprises: combining at least one isolated probe, tool or reagent of the fourth aspect with a sample; and identifying, partially identifying, or classifying at least one bacterium, yeast organism, or filamentous fungus based on the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of the yeast organism or filamentous fungus; wherein at least one SNP in at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762 and 776 of the 16S rRNA gene set forth in SEQ ID NO:1.
[0022] According to a sixth aspect of the invention there is provided an array (in particular a microarray) comprising a plurality of said isolated probes, tools or reagents of the fourth aspect.
[0023] According to a seventh aspect of the invention there is provided a biochip comprising a solid substrate and at least one isolated probe, tool or reagent of the fourth aspect.
[0024] According to an eighth aspect of the invention there is provided a kit or assay.
[0025] In one embodiment of the eighth aspect, the kit or assay is for classifying or identifying at least one bacteria or at least one yeast organism or filamentous fungus in a sample, said kit or assay comprising: at least one probe, tool or reagent of the fourth aspect; an array of the sixth aspect; and / or a biochip of the seventh aspect.
[0026] In another embodiment of the eighth aspect, the kit or assay is capable of distinguishing between a sample comprising at least one bacterium, yeast organism or filamentous fungus and a sample not comprising at least one bacterium, yeast organism or filamentous fungus, and the kit or assay comprises a probe, tool or reagent of the fourth aspect.
[0027] According to a ninth aspect of the present invention there is provided at least one single nucleotide polymorphism (SNP). In one embodiment, at least one of said SNPs is present in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus, for use as an indicator for classifying, identifying, or partially identifying at least one bacterium, yeast organism, or filamentous fungus in a sample; wherein at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653 of the 16S rRNA gene set forth in SEQ ID NO:1; or At least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is in or corresponds to the 16S rRNA gene set forth in SEQ ID NO:43. In another embodiment, at least one of said SNPs is present in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus, for use as an indicator for classifying, identifying, or partially identifying at least one bacterium, yeast organism, or filamentous fungus in a sample; wherein at least one SNP in at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762 and 776 of the 16S rRNA gene set forth in SEQ ID NO:1.
[0028] According to a tenth aspect of the present invention there is provided the use of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus, as defined in the first aspect, or at least one isolated probe, tool or reagent of the fourth aspect, in the identification, partial identification or classification of at least one bacterium, yeast organism or filamentous fungus in a sample, wherein said at least one bacterium, yeast organism or filamentous fungus is identified, partially identified or classified based on the presence or absence of at least one SNP in at least a portion of a 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product from the sample.
[0029] According to an eleventh aspect of the invention there is provided a kit comprising probes, tools or reagents for use in the method of any one of the first, second, third or fifth aspects of the invention.
[0030] Further aspects of the invention are provided below.
[0031] According to a twelfth aspect of the invention there is provided at least one single nucleotide polymorphism (SNP) in a 16S rRNA gene for or when used in the identification of at least one bacterium in a sample or the classification of a bacterium in a sample; or at least one single nucleotide polymorphism (SNP) in an 18S rRNA gene for or when used in the identification of at least one yeast organism or filamentous fungus in a sample or the classification of a yeast organism or filamentous fungus in a sample.
[0032] According to a thirteenth aspect of the present invention there is provided at least one said probe, tool or reagent for or when used in the identification of one bacterium in a sample or the classification of one bacterium in a sample, which is capable of specifically binding, detecting or identifying at least a portion of a 16S rRNA gene in a sample containing at least one SNP; or at least one said probe, tool or reagent for or when used in the identification of one yeast organism or filamentous fungus in a sample or the classification of one yeast organism or filamentous fungus in a sample, which is capable of specifically binding, detecting or identifying at least a portion of an 18S rRNA gene in a sample containing at least one SNP.
[0033] According to a fourteenth aspect of the present invention there is provided at least one said probe, tool or reagent comprising an oligonucleotide having a nucleotide sequence as set out in any one of SEQ ID NOs: 16 to 35, 56 or 57 for or when used in the identification of at least one bacterium in a sample or the classification of at least one bacterium in a sample; or at least one probe, tool or reagent comprising an oligonucleotide having a nucleotide sequence as set out in any one of SEQ ID NOs: 53 to 55 for or when used in the identification of at least one yeast organism or filamentous fungus in a sample or the classification of at least one yeast organism or filamentous fungus in a sample.
[0034] According to a fifteenth aspect of the present invention there is provided the use of at least one SNP as defined in the twelfth aspect, or at least one probe, tool or reagent as defined in the thirteenth or fourteenth aspect, in the identification of at least one bacterium in a sample or the classification of a bacterium in a sample, wherein at least one said bacterium is identified or classified based on the presence of at least one SNP in a 16S rRNA gene from said sample; or the use of at least one SNP as defined in the twelfth aspect, or at least one probe, tool or reagent as defined in the thirteenth or fourteenth aspect, in the identification of at least one yeast organism or filamentous fungus in a sample or the classification of at least one yeast organism or filamentous fungus in a sample, wherein at least one said yeast organism or filamentous fungus is identified or classified based on the presence of at least one SNP in an 18S rRNA gene from said sample.
[0035] According to a sixteenth aspect of the present invention there is provided a method of identifying at least one bacterium in a sample comprising analysing a 16S rRNA gene from the sample for at least one SNP as defined in the first aspect, wherein the at least one bacterium is identified based on the presence of the at least one SNP; or a method of identifying at least one yeast organism or filamentous fungus in a sample comprising analysing an 18S rRNA gene from the sample for at least one SNP as defined in the twelfth aspect, wherein the at least one yeast organism or filamentous fungus is identified based on the presence of the at least one SNP.
[0036] In one embodiment, a method of identifying at least one bacterium in a sample is provided, comprising analyzing nucleic acid from the sample for at least one SNP located in a bacterial 16S rRNA gene at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, and 653 of the 16S rRNA gene as set forth in SEQ ID NO:1, wherein the at least one bacterium is identified based on the presence of the at least one SNP.
[0037] According to a 17th aspect of the present invention there is provided a method of classifying bacteria in a sample comprising analysing a 16S rRNA gene from the sample for at least one SNP as defined in the first aspect, wherein the bacteria is classified based on the presence of the at least one SNP; or a method of classifying at least one yeast organism or filamentous fungus in a sample comprising analysing an 18S rRNA gene from the sample for at least one SNP as defined in the 12th aspect, wherein the at least one yeast organism or filamentous fungus is classified based on the presence of the at least one SNP.
[0038] According to an eighteenth aspect of the present invention there is provided a method for identifying at least one bacterium in a sample, comprising the steps of: combining at least one probe, tool or reagent as defined in the thirteenth or fourteenth aspect with the sample; and or, a method comprising identifying at least one bacterium based on the presence of at least one SNP in a 16S rRNA gene from a sample as broadly described above; or 1. A method for identifying at least one yeast organism or filamentous fungus in a sample, comprising: combining at least one probe, tool or reagent as defined in the thirteenth or fourteenth aspect with the sample; and Methods are provided which include identifying at least one yeast organism or filamentous fungus based on the presence of at least one SNP in an 18S rRNA gene from a sample as broadly described above.
[0039] According to a nineteenth aspect of the present invention there is provided a method for classifying bacteria in a sample comprising the steps of: combining at least one probe, tool or reagent as defined in the thirteenth or fourteenth aspect with the sample; and Classifying bacteria based on the presence of at least one SNP in the 16S rRNA gene from a sample as broadly described above; or 1. A method for classifying at least one yeast organism or filamentous fungus in a sample, comprising: combining at least one probe, tool or reagent as defined in the thirteenth or fourteenth aspect with the sample; and Methods are provided that include classifying at least one yeast organism or filamentous fungus based on the presence of at least one SNP in an 18S rRNA gene from a sample as broadly described above.
[0040] According to a twentieth aspect of the present invention there is provided a method of diagnosing a bacterial infection in a subject comprising analysing a 16S rRNA gene from a sample obtained from the subject for at least one SNP as defined in the twelfth aspect, wherein the bacterial infection is diagnosed by identifying at least one causative bacteria in the sample based on the presence of the at least one SNP; or a method of diagnosing an infection of at least one yeast organism or filamentous fungus in a subject comprising analysing an 18S rRNA gene from a sample obtained from the subject for at least one SNP as defined in the twelfth aspect, wherein the infection of at least one yeast organism or filamentous fungus is diagnosed by identifying at least one causative yeast organism or filamentous fungus in the sample based on the presence of the at least one SNP.
[0041] According to a twenty-first aspect of the present invention there is provided a method of diagnosing a bacterial infection in a subject comprising the steps of: combining at least one probe, tool or reagent as defined in the thirteenth or fourteenth aspect with a sample obtained from the subject; and or diagnosing a bacterial infection by identifying at least one causative bacterium in a sample based on the presence of at least one SNP in a 16S rRNA gene from the sample as broadly described above; or 1. A method for diagnosing an infection with at least one yeast organism or filamentous fungus in a subject, comprising: combining at least one probe, tool or reagent as defined in the thirteenth or fourteenth aspect with a sample obtained from the subject; and Methods are provided that include diagnosing infection with at least one yeast organism or filamentous fungus by identifying at least one causative bacterium in a sample based on the presence of at least one SNP in an 18S rRNA gene from the sample as broadly described above.
[0042] According to a twenty-second aspect of the present invention there is provided a method of treating a subject having a bacterial infection comprising the steps of: Diagnosing a bacterial infection by identifying at least one causative bacterium in a sample by the method defined in the twentieth or twenty-first aspect; and administering to a subject a therapy or treatment for treating at least one identified causative bacteria, thereby treating the bacterial infection; or 1. A method of treating a subject having an infection with at least one yeast organism or mold fungus, comprising: diagnosing an infection with at least one yeast organism or filamentous fungus by identifying at least one causative bacterium in a sample by the method defined in the twentieth or twenty-first aspect; and Methods are provided that include administering to a subject a therapy or treatment for treating at least one identified causative yeast organism or mold fungus, thereby treating the bacterial infection.
[0043] According to a twenty-third aspect of the present invention there is provided an array of oligonucleotide probes for the identification of at least one bacterium in a sample or the classification of bacteria in a sample, the probe comprising an oligonucleotide that hybridizes to at least one SNP in a 16S rRNA gene in the sample as broadly described above; or an array of oligonucleotide probes for the identification of at least one yeast organism or filamentous fungus in a sample or the classification of at least one yeast organism or filamentous fungus in a sample, the probe comprising an oligonucleotide that hybridizes to at least one SNP in an 18S rRNA gene in the sample as broadly described above.
[0044] According to a twenty-fourth aspect of the invention there is provided a microarray comprising oligonucleotide probes for the identification of at least one bacterium in a sample or the classification of a bacterium in a sample, said probe comprising an oligonucleotide that hybridizes to at least one SNP in a 16S rRNA gene in a sample as broadly described above; or a microarray comprising oligonucleotide probes for the identification of at least one yeast organism or filamentous fungus in a sample or the classification of at least one yeast organism or filamentous fungus in a sample, said probe comprising an oligonucleotide that hybridizes to at least one SNP in an 18S rRNA gene in a sample as broadly described above.
[0045] According to a twenty-fifth aspect of the present invention there is provided a biochip comprising a solid substrate and at least one oligonucleotide probe for identification of at least one bacterium in a sample or classification of a bacterium in a sample, wherein at least one said probe comprises an oligonucleotide that hybridizes to at least one SNP in a 16S rRNA gene in a sample as broadly described above; or a biochip comprising a solid substrate and at least one oligonucleotide probe for identification of at least one yeast organism or filamentous fungus in a sample or classification of at least one yeast organism or filamentous fungus in a sample, wherein at least one said probe comprises an oligonucleotide that hybridizes to at least one SNP in a 18S rRNA gene in a sample as broadly described above.
[0046] According to a twenty-sixth aspect of the present invention there is provided a kit or assay for the identification of at least one bacterium in a sample or the classification of bacteria in a sample comprising at least one probe, tool or reagent as described above; an array of oligonucleotide probes as described above; a microarray as described above; and / or a biochip as described above; or a kit or assay for the identification of at least one yeast organism or filamentous fungus in a sample or the classification of at least one yeast organism or filamentous fungus in a sample comprising at least one probe, tool or reagent as described above; an array of oligonucleotide probes as described above; a microarray as described above; and / or a biochip as described above.
[0047] According to a 27th aspect of the invention, there is provided a method of identifying, partially identifying, classifying or diagnosing an infection in a subject. In one embodiment of the 27th aspect, the infection is a bacterial, yeast organism or filamentous fungal infection, and the method comprises testing a biological sample obtained from the subject for a characteristic of at least one bacterial 16S rRNA gene or gene product or a portion thereof, or at least one yeast organism or filamentous fungal 18S rRNA gene or gene product or a portion thereof, wherein the testing comprises detecting at least one single nucleotide polymorphism (SNP) in at least one bacterial 16S rRNA gene or gene product or a portion thereof, or at least one yeast organism or filamentous fungal 18S rRNA gene or gene product or a portion thereof; At least one SNP in a bacterial 16S rRNA gene or gene product or portion thereof is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, and 653 of the 16S rRNA gene set forth in SEQ ID NO:1; or At least one SNP in a bacterial 16S rRNA gene or gene product or a portion thereof is in or corresponds to the 16S rRNA gene set forth in SEQ ID NO: 43; or At least one bacterium, yeast organism, or filamentous fungus in the sample is identified, partially identified, classified, or diagnosed based on the presence or absence of at least one SNP. In another embodiment of the twenty-seventh aspect, the infection is a bacterial, yeast organism, or filamentous fungal infection, and the method comprises testing a biological sample from the subject for a characteristic of at least one bacterial 16S rRNA gene or gene product or portion thereof, or at least one yeast organism or filamentous fungal 18S rRNA gene or gene product or portion thereof, wherein the testing comprises detecting at least one single nucleotide polymorphism (SNP) in the at least one bacterial 16S rRNA gene or gene product or portion thereof, or at least one yeast organism or filamentous fungal 18S rRNA gene or gene product or portion thereof; at least one SNP in the bacterial 16S rRNA gene or gene product or portion thereof is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of the 16S rRNA gene set forth in SEQ ID NO:1; At least one bacterium, yeast organism, or filamentous fungus in the sample is identified, partially identified, classified, or diagnosed based on the presence or absence of at least one SNP.
[0048] Features of the first to twenty-seventh aspects of the invention, where applicable, may be as follows.
[0049] In one embodiment, the at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is selected from SNPs at positions corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762 and 776 of the 16S rRNA gene as set forth in SEQ ID NO: 1. In some embodiments, multiple SNPs can be used in the methods of the invention. For example, at least two SNPs, at least three SNPs, at least four SNPs, at least five SNPs, at least six SNPs, at least seven SNPs, at least eight SNPs, at least nine SNPs, at least ten SNPs or even at least eleven SNPs can be used.
[0050] In one embodiment, the at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product is selected from SNPs at positions corresponding to positions 273, 378, 412, 440, 488, 647 and 653 of the 16S rRNA gene as set forth in SEQ ID NO: 1. In some embodiments, multiple SNPs can be used in the methods of the invention. For example, at least two SNPs, at least three SNPs, at least four SNPs, at least five SNPs, at least six SNPs or even at least seven SNPs can be used.
[0051] In another embodiment, the at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product may be in or correspond to the 16S rRNA gene set forth in SEQ ID NO: 43. The at least one SNP in at least a portion of a bacterial 16S rRNA gene or gene product set forth in SEQ ID NO: 43 may be at a position corresponding to at least one of positions 746, 764, 771 or 785 of the 16S rRNA gene set forth in SEQ ID NO: 43 (or positions 737, 755, 762 or 776 of the 16S rRNA gene set forth in SEQ ID NO: 1). At least one SNP, at least two SNPs, at least three SNPs or at least four SNPs may be used.
[0052] In another embodiment, the at least one SNP in at least a portion of the 18S rRNA gene or gene product of the yeast organism or filamentous fungus may be in or correspond to the 18S rRNA gene set forth in SEQ ID NO: 37. The at least one SNP in at least a portion of the 18S rRNA gene or gene product of the yeast organism or filamentous fungus may be at a position corresponding to at least one of positions 343, 371, 388, 416 and 467 of the 18S rRNA gene set forth in SEQ ID NO: 37. At least one of said SNPs, at least two of said SNPs, at least three of said SNPs, at least four of said SNPs or at least five of said SNPs may be used.
[0053] In a further embodiment, the method comprises: extracting at least a portion of a bacterial 16S rRNA gene or gene product from a sample, or at least a portion of a yeast organism or filamentous fungal 18S rRNA gene or gene product from a sample; single nucleotide polymorphisms in the bacterial 16S rRNA gene at positions corresponding to positions 273, 378, 412, 440, 488, 647, and 653 of the 16S rRNA gene set forth in SEQ ID NO:1; or Single nucleotide polymorphisms in the bacterial 16S rRNA gene at positions corresponding to positions 746, 764, 771, and 785 of the 16S rRNA gene set forth in SEQ ID NO:43; or Single nucleotide polymorphisms in the 18S rRNA gene of a yeast organism or a filamentous fungus at positions corresponding to positions 343, 371, 388, 416, and 467 of the 18S rRNA gene set forth in SEQ ID NO:37. This includes analyzing for the presence or absence of
[0054] In a further embodiment, the method comprises: extracting at least a portion of a bacterial 16S rRNA gene or gene product from a sample, or at least a portion of a yeast organism or filamentous fungal 18S rRNA gene or gene product from a sample; single nucleotide polymorphisms at positions corresponding to at least four of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 in the 16S rRNA gene set forth in SEQ ID NO:1, within at least a portion of a bacterial 16S rRNA gene or gene product; or Single nucleotide polymorphisms in the 18S rRNA gene of a yeast organism or a filamentous fungus at positions corresponding to positions 343, 371, 388, 416, and 467 of the 18S rRNA gene set forth in SEQ ID NO:37. This includes analyzing for the presence or absence of
[0055] In some embodiments, the one or more bacteria are selected from among mammalian (e.g., human) associated bacteria, soil associated bacteria, and water associated bacteria. In certain embodiments, the one or more bacteria may be one or more sepsis associated bacteria.
[0056] In certain embodiments, the one or more bacteria are selected from among at least one of the following: Acinetobacter spp.; Actinobaccillus spp.; Actinomadura spp.; Actinomyces spp.; Actinoplanes spp.; Aeromonas spp.; Agrobacterium spp.; Alistipes spp.; Anaerococcus spp.; Arthrobacter spp.; Bacillus spp.; Bacteroides spp.; Brucella spp.; Bulleidia spp.; Burkholderia spp.; Cardiobacterium spp.; Citrobacter spp.; Clostridium spp.; Cornyebacterium spp.; Dermatophilus spp.; Dorea spp.; Enterobacter spp.; Enterococcus spp.; Erysipelothrix Escherichia spp.;Eubacterium spp.;Ewardsiella spp.;Faecalibacterium spp.;Filifactor spp.;Finegoldia spp.;Flavobacterium spp.;Francisella spp.;Gallicola spp.;Haemophilus spp.;Helococcus spp.;Holdemania spp.;Hyphomicrobium spp.;Klebsiella spp.;Lactobacillus spp.;Legionella spp.;Listeria spp.;Methylobacterium spp.;Micrococcus spp.;Micromonospora spp.;Mobiluncus spp.;Moraxella spp.;Morganella spp.;Mycobacterium spp.;Neisseria spp.;Nocardia spp.;Paenibacillus spp.;Parabacteroides spp.;Pasteurella spp.;Peptoniphilus spp.;Peptostreptococcus spp.;Planococcus spp.;Planomicrobium spp.;Plesiomonas spp.;Porphyromonas spp.;Prevotella spp.;Propionibacterium spp.;Proteus spp.;Providentia spp.;Pseudomonas spp.;Ralstonia spp.;Rhodococcus spp.;Roseburia spp.;Ruminococcus spp.;Salmonella spp.;Sedimentibacter spp.;Serratia spp.;Shigella spp.;Solobacterium spp.;Sphingomonas spp.;Staphylococcus spp.;Stenotrophomonas spp.;Streptococcus spp.;Streptomyces spp.;Tissierella spp.;Vibrio spp.;and Yersinia spp.
[0057] In some more specific embodiments, the one or more bacteria are selected from at least one of the following: Acinetobacter baumannii; Acinetobacter calcoaceticus; Bacteroides fragilis; Bacteroides vulgatus; Citrobacter freundii; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus avium; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella oxytoca; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus saprophyticus; Stenotrophomonas maltophilia; Streptococcus agalactiae; Streptococcus anginosus; Streptococcus constellatus; Streptococcus intermedius; Streptococcus milleri; Streptococcus mitis; Streptococcus mutans; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus sanguinis; and Streptococcus sobrinus.
[0058] In certain embodiments, the one or more bacteria are selected from among at least one of the following: Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae; and Streptococcus pyogenes.
[0059] In certain embodiments, the one or more bacteria are selected from among at least one of the following: Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes; Listeria monocytogenes; Clostridium perfringens; Corynebacterium jeikeium; Bacteroides fragilis; Neisseria meningitides; Haemophilus influenzae; Salmonella sp.; and Staphylococcus epidermidis.In another embodiment, the one or more bacteria are selected from among at least one of the following: Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes; Listeria monocytogenes; Clostridium perfringens; Corynebacterium jeikeium; Bacteroides fragilis; Neisseria meningitides; Haemophilus influenzae; Salmonella sp.; Staphylococcus epidermidis; Bacillus anthracis, Clostridium botulinum, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei.
[0060] In one embodiment, the one or more bacteria are security-sensitive biological agents (SSBAs). The SSBAs may be Tier 1 or Tier 2 agents. Exemplary Tier 1 agents include one or more of the following: Bacillus anthracis (anthrax) and Yesinia pestis (plague). Exemplary Tier 2 agents include one or more of the following: Clostridium botulinum (botulism, especially toxin-producing strains); Francisella tularensis (tularemia); Salmonella Typhi (typhoid fever) and Vibrio cholerae (especially cholera serotypes O1 or O139). In one embodiment, the one or more bacteria are selected from among at least one of the group consisting of Bacillus anthracis, Clostridium botulinum, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei.
[0061] In one embodiment, the yeast organism can be selected from among at least one of the following: Candida spp., Cryptococcus spp., and Rhodotorula spp. Exemplary Candida spp. can include at least one of Candida albicans, Candida tropicalis, Candida stellatoidea, Candida krusei, Candida parapsilosis, Candida glabrata, Candida guilliermondii, Candida viswanathii, Candida auris, and Candida lusitaniae. Exemplary Cryptococcus spp. can include at least one of Cryptococcus neoformans and Cryptococcus gattii. Exemplary Rhodotorula spp. can be Rhodotorula mucilaginosa.
[0062] In one embodiment, the filamentous fungus can be selected from at least one of the following: Aspergillus spp. and Fusarium spp. Exemplary Fusarium spp. can include at least one of Fusarium solani, Fusarium oxysporum, Fusarium verticillioides, Fusarium proliferatum, Fusarium avenaceum, Fusarium bubigeum, Fusarium culmorum, Fusarium graminearum, Fusarium langsethiae, Fusarium poae, Fusarium sporotrichioides, Fusarium tricinctum, and Fusarium virguliforme; in particular at least one of Fusarium solani, Fusarium oxysporum, Fusarium verticillioides, and Fusarium proliferatum. Exemplary Aspergillus spp. can include at least one of Aspergillus fumigatus, Aspergillus flavus, Aspergillus clavatus, Aspergillus lentulus, Aspergillus terreus, and Aspergillus nidulans; particularly at least one of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus clavatus; more particularly Aspergillus fumigatus.
[0063] In one embodiment, the yeast organism or filamentous fungus is at least one of the group consisting of: Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium sp., Aspergillus fumigatus, and Cryptococcus neoformans.
[0064] In one embodiment, the bacterium, yeast organism or filamentous fungus is a human pathogen.
[0065] In some embodiments, the methods of the invention can be used to analyze blood from a subject with systemic inflammatory response syndrome (SIRS) to determine the cause of SIRS (e.g., bacteria, yeast organisms, or mold fungi). In other embodiments, the methods of the invention can be used to determine whether a subject has sepsis with a bacterial, yeast organism, or mold fungal source of infection. In both embodiments, the methods of the invention can be used to determine the presence, differentiate, and / or identify bacteria, yeast organisms, or mold fungi present in a sample.
[0066] SIRS is an overwhelming systemic response that can have an infectious or non-infectious etiology (i.e., infection-negative SIRS or inSIRS). Sepsis is SIRS that occurs during infection. Sepsis in this case is diagnosed by the clinician (when infection is suspected) or through organism culture. SIRS and sepsis are defined by several non-specific host response parameters, including changes in cardiac and respiratory rates, body temperature, and white blood cell count (Levy et al., 2003; Reinhart et al., 2012).
[0067] In some embodiments, at least one SNP or at least one probe, tool or reagent can be used to classify bacteria in a sample as one or more bacteria that are gram-positive or one or more bacteria that are gram-negative.
[0068] For example, in some embodiments, one or more bacteria may be classified as Gram-positive based on any one of the above SNPs, particularly at least one of positions 273, 378, 412, 440, 488, 647, and 653 of the 16S rRNA gene as set forth in SEQ ID NO: 1. In one such embodiment, one or more bacteria may be classified based on SNPs at positions corresponding to positions 273 and 653 of the 16S rRNA gene as set forth in SEQ ID NO: 1, where an A at position 273 and a T at position 653 determine the one or more bacteria to be Gram-positive.
[0069] For example, in another embodiment, one or more bacteria can be classified as Gram-positive based on at least one SNP at a position corresponding to position 440 of the 16S rRNA gene as set forth in SEQ ID NO:1, where a T at position 440 determines the one or more bacteria to be Gram-positive. Conversely, an absence of a T at position 440 determines the one or more bacteria to be Gram-negative.
[0070] In yet other embodiments, the at least one SNP or at least one probe, tool or reagent can be used to classify a group of bacteria, yeast organisms or filamentous fungi in a sample.
[0071] For example, in some embodiments, bacteria can be classified as belonging to a particular genus based on at least one SNP selected from the SNPs listed above. In one such embodiment, bacteria can be classified as belonging to a particular genus based on at least one SNP selected from the SNPs at positions corresponding to positions 412 and 647 of the 16S rRNA gene as set forth in SEQ ID NO:1. For example, one or more bacteria in a sample can be classified as belonging to the genus Staphylococcus when there is a T at position 412. For example, one or more bacteria in a sample can be classified as belonging to the genus Enterococcus when there is a G at position 647.
[0072] In yet other embodiments, the at least one SNP or at least one probe, tool or reagent may be used to identify bacteria in a sample as described above.
[0073] For example, the bacterium Enterobacter cloacae can be identified in a sample based on at least one SNP at a position corresponding to position 653 of the 16S rRNA gene set forth in SEQ ID NO:1, where a G at position 653 identifies the bacterium Enterobacter cloacae.
[0074] For example, bacteria selected from Streptococcus pneumoniae, Streptococcus agalactiae and Streptococcus pyogenes can be identified in a sample based on SNPs at positions corresponding to positions 378 and 488 of the 16S rRNA gene as set forth in SEQ ID NO:1, where the bacteria are: Streptococcus pneumoniae when there is an A at position 378 and a T at position 488; Streptococcus agalactiae when there is an A at position 378 and an A at position 488; and Streptococcus pyogenes when there is a G at position 378 and an A at position 488.
[0075] For example, in one embodiment, bacteria selected from among Acinetobacter calcoaceticus; Enterobacter cloacae; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes can be identified in a sample based on SNPs at positions corresponding to positions 273, 378, 412, 440, 488, 647 and 653 of the 16S rRNA gene as set forth in SEQ ID NO:1, where the bacteria are: Acinetobacter calcoaceticus when there is an A at position 273, 440 and 647; Enterobacter cloacae when there is a G at position 653; and Escherichia coli when there is a T at position 273 and a T at position 653. coli with a T at position 273, Cs at positions 488 and 647, and A at position 653; Proteus mirabilis with a C at positions 440 and 488, and a T at position 647; Pseudomonas aeruginosa with an A at position 440 and a T at position 647; Streptococcus agalactiae with A at positions 378, 488, and 647; Streptococcus pneumoniae with a T at positions 488 and 647; and Streptococcus pyogenes with a G at position 378, and A at positions 488 and 647.
[0076] For example, in another embodiment, bacteria selected from among Acinetobacter calcoaceticus; Enterobacter cloacae; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes may be identified in a sample based on the presence of the SNPs set out in the following table:
[0077] [Table 1]
[0078] For example, in another embodiment, bacteria selected from among Escherichia coli, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Proteus mirabilis, Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter calcoaceticus, Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus, Clostridium perfringens, Corynebacterium jeikeium, Bacteroides fragilis, Neisseria meningitidis, Haemophilus influenzae, Serratia marcescens, Salmonella sp. and Staphylococcus epidermidis can be identified in a sample based on the presence of the SNPs set out in the table below:
[0079] [Table 2]
[0080] In another embodiment, a bacterium selected from among Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei can be identified in a sample based on a SNP at a position corresponding to position 746, 764, 771 or 785 of the 16S rRNA gene as set forth in SEQ ID NO: 43, wherein the bacterium is: Bacillus anthracis when there is a T at position 746, an A at position 764, a C at position 771 and a G at position 785; Clostridium botulinum type B when there is a T at position 746, an A at position 764, a T at position 771, and a T at position 785; Clostridium botulinum type C when there is a C at position 746, an A at position 764, a T at position 771, and a T at position 785; Clostridium botulinum type D when there is a C at position 746, a G at position 764, a C at position 771, and a G at position 785; Clostridium botulinum type G when there is a C at position 746, a G at position 764, a T at position 771, and a G at position 785; Yersinia pestis when there is a T at position 746, an A at position 764, a G at position 771, and a G at position 785; Francisella tularensis; when there is a C at position 746, an A at position 764, a T at position 771, and a G at position 785, it is Vibrio cholerae; when there is a C at position 746, a G at position 764, a C at position 771, and a G at position 785, it is Burkholderia pseudomallei.
[0081] For example, in another embodiment, bacteria selected from among Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae, and Burkholderia pseudomallei may be identified in a sample based on the presence of the SNPs set out in the following table:
[0082] [Table 3]
[0083] The cumulative discrimination index of the four SNPs used to identify the above organisms is 0.667 for 1 SNP; 0.889 for 2 SNPs; 0.944 for 3 SNPs; and 0.972 for 4 SNPs.
[0084] Position 746 of the 16S rRNA gene shown in SEQ ID NO: 43 corresponds to position 737 of the 16S rRNA gene shown in SEQ ID NO: 1. Position 764 of the 16S rRNA gene shown in SEQ ID NO: 43 corresponds to position 755 of the 16S rRNA gene shown in SEQ ID NO: 1. Position 771 of the 16S rRNA gene shown in SEQ ID NO: 43 corresponds to position 762 of the 16S rRNA gene shown in SEQ ID NO: 1. Position 785 of the 16S rRNA gene shown in SEQ ID NO: 43 corresponds to position 776 of the 16S rRNA gene shown in SEQ ID NO: 1.
[0085] Thus, in another embodiment, a bacterium selected from among Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei may be identified in a sample based on a SNP at a position corresponding to position 737, 755, 762 or 776 of the 16S rRNA gene as set forth in SEQ ID NO:1, wherein the bacterium is: Bacillus anthracis when there is a T at position 737, an A at position 755, a C at position 762 and a G at position 776; Clostridium botulinum type B when there is a T at position 737, an A at position 755, a T at position 762, and a T at position 776; Clostridium botulinum type C when there is a C at position 737, an A at position 755, a T at position 762, and a T at position 776; Clostridium botulinum type D when there is a C at position 737, a G at position 755, a C at position 762, and a G at position 776; Clostridium botulinum type G when there is a C at position 737, a G at position 755, a T at position 762, and a G at position 776; Yersinia pestis when there is a T at position 737, an A at position 755, a G at position 762, and a G at position 776; Francisella tularensis; when there is a C at position 737, an A at position 755, a T at position 762, and a G at position 776, it is Vibrio cholerae; when there is a C at position 737, a G at position 755, a C at position 762, and a G at position 776, it is Burkholderia pseudomallei.
[0086] In another embodiment, a yeast organism or filamentous fungus selected from among Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium spp., Aspergillus fumigatus and Cryptococcus neoformans can be identified in a sample based on SNPs at positions corresponding to positions 343, 371, 388, 416 and 467 of the 18S rRNA gene as set forth in SEQ ID NO:37, wherein the yeast organism or filamentous fungus is: Candida albicans when there is a C at position 343, an A at position 371, a T at position 388, a G at position 416 and a G at position 467; tropicalis when there is a C at position 343, an A at position 371, a C at position 388, a G at position 416, and a G at position 467; Candida parapsilosis when there is a T at position 343, an A at position 371, a C at position 388, a G at position 416, and a G at position 467; Candida glabrata when there is a T at position 343, an A at position 371, a C at position 388, a G at position 416, and a G at position 467; Fusarium spp. when there is a C at position 343, a C at position 371, a T at position 388, a C at position 416, and a G at position 467; Aspergillus when there is a C at position 343, a C at position 371, a T at position 388, a C at position 416, and a G at position 467 fumigatus when there is a C at position 343, an A at position 371, a T at position 388, a T at position 416, and a G at position 467; Cryptococcus neoformans when there is a C at position 343, an A at position 371, a T at position 388, a T at position 416, and a G at position 467.
[0087] For example, in another embodiment, a yeast organism or filamentous fungus selected from among Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium spp., Aspergillus fumigatus, and Cryptococcus neoformans may be identified in a sample based on the presence of the SNPs set forth in the following table:
[0088] [Table 4]
[0089] A bacterium, yeast organism or filamentous fungus can be identified or classified, in part, based on one or more of the above SNPs.
[0090] In one embodiment, nucleic acid is extracted from the sample prior to analysis in the method of the present invention (particularly in the first and second aspects). In another embodiment, the analysis step in the method (particularly in the first and second aspects) can include amplification of nucleic acid. Nucleic acid can be amplified by any method known in the art, including but not limited to polymerase chain reaction (PCR), ligase chain reaction (LCR) and reverse transcription-polymerase chain reaction (RT-PCR), using one or more oligonucleotides / primers that amplify transcribed RNA.
[0091] SNPs can be analyzed by any method known in the art, including but not limited to: high-resolution melting analysis, 5' nuclease digestion (including 5' nuclease digestion), molecular beacons, oligonucleotide ligation, microarrays, restriction fragment length polymorphism; antibody detection methods; direct sequencing or any combination thereof. In one embodiment, the analyzing step in the method (particularly in the first and second aspects of the invention) comprises determining the presence or absence of at least one SNP using high-resolution melting analysis, 5' nuclease digestion, molecular beacons, oligonucleotide ligation, microarrays, restriction fragment length polymorphism, antibody detection methods; direct sequencing or any combination thereof. SNPs can be detected by any method known in the art, including, but not limited to: polymerase chain reaction (PCR); ligase chain reaction (LCR); hybridization analysis; high-resolution melting analysis; digestion with nucleases, including 5' nuclease digestion; molecular beacons; oligonucleotide ligation; microarrays; restriction fragment length polymorphism; antibody detection methods; direct sequencing; or any combination thereof.
[0092] For example, in some embodiments, bacterial identification or bacterial classification may be further based on DNA melting characteristics, preferably high-resolution melting analysis, of the SNPs and their surrounding DNA sequences as broadly described above.
[0093] For example, in some such embodiments, the methods of the present invention may further comprise high-resolution melting (HRM) analysis to further analyze the DNA melting properties of the SNPs and their surrounding DNA sequences as broadly described above. In certain embodiments, the HRM analysis involves the formation of a DNA amplification product (i.e., an amplicon) containing at least one of the SNPs and at least one intercalating fluorescent dye, and the determination of its melting temperature (T m) to heat the DNA amplification products. HRM is monitored in real time using a fluorescent dye that is incorporated into the DNA amplification products. Fluorescence levels are monitored as temperature is increased as fluorescence decreases as the amount of double-stranded DNA decreases. The changes in fluorescence and temperature can be plotted on a graph known as a melting curve.
[0094] As one of skill in the art will appreciate, the T of a DNA amplification product at which the two DNA strands separate. m is predictable and depends on the sequence of nucleotide bases that form the DNA amplification product. Therefore, the melting curves appear differently, and it is possible to distinguish DNA amplification products, including those that contain polymorphisms (i.e., one or more SNPs). Indeed, in some embodiments, it is possible to distinguish DNA amplification products that contain the same polymorphism based on the difference in the surrounding DNA sequence.
[0095] For example, bacteria selected from among Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes can be identified in a sample based on the presence of the SNPs shown in the table below and the DNA melting properties of the SNPs and their surrounding DNA sequences:
[0096] [Table 5]
[0097] For example, bacteria selected from among Escherichia coli, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Proteus mirabilis, Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter calcoaceticus, Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus, Clostridium perfringens, Corynebacterium jeikeium, Bacteroides fragilis, Neisseria meningitidis, Haemophilus influenzae, Serratia marcescens, Salmonella sp., Staphylococcus epidermidis can be identified in a sample based on the presence of the SNPs shown in Table 2 and the DNA melting properties of the SNPs and their surrounding DNA sequences.
[0098] In one embodiment, bacteria selected from Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes can be identified in a sample based on SNPs at positions corresponding to positions 273, 378, 412, 440, 488, 647 and 653 of the 16S rRNA gene set forth in SEQ ID NO:1 and high resolution melting curve analysis of the SNPs and their surrounding DNA.
[0099] For example, bacteria selected from among Acinetobacter calcoaceticus; Enterobacter cloacae; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes can be identified in a sample based on the above SNP positions and / or high-resolution melting curve analysis of the SNPs and their surrounding DNA.
[0100] In some embodiments, bacteria selected from Staphylococcus aureus; Staphylococcus epidermidis; Enterococcus faecalis; Enterococcus faecium; Serratia marcescens and Enterobacter aerogenes can be individually identified in a sample based on SNPs at positions corresponding to positions 412, 440, 488 and 647 of the 16S rRNA gene as set forth in SEQ ID NO:1, where: Staphylococcus aureus and Staphylococcus epidermidis can be identified when there is a T at position 412 and can then be further differentiated from each other based on high-resolution melting curve analysis of the DNA surrounding the SNP at position 412; Enterococcus faecalis and Enterococcus faecium can be identified when there is a G at position 647 and can then be further differentiated from each other based on high-resolution melting curve analysis of the DNA surrounding the SNP at position 647; Serratia marcescens and Enterobacter aerogenes can be individually identified in a sample based on SNPs at positions corresponding to positions 412, 440, 488 and 647 of the 16S rRNA gene as set forth in SEQ ID NO:1, where: aerogenes can be identified when they have a C at positions 440 and 647 and a T at position 488, and can then be further distinguished from each other based on high-resolution melting curve analysis of the DNA surrounding the SNP at any one of positions 440, 488 and 647.
[0101] In other embodiments, a bacterium selected from Enterococcus faecalis; Enterococcus faecium; Streptococcus agalactiae and Streptococcus pyogenes can be identified in a sample based on at least one SNP at a position corresponding to position 378 of the 16S rRNA gene set forth in SEQ ID NO:1 and high resolution melting curve analysis of the DNA surrounding the SNP at position 378.
[0102] For example, bacteria selected from among Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei can be identified in a sample based on the presence of the SNPs and the DNA melting properties of the SNPs and their surrounding DNA sequences as shown in the following table:
[0103] [Table 6]
[0104] As described above, position 746 of the 16S rRNA gene shown in SEQ ID NO: 43 corresponds to position 737 of the 16S rRNA gene shown in SEQ ID NO: 1. Position 764 of the 16S rRNA gene shown in SEQ ID NO: 43 corresponds to position 755 of the 16S rRNA gene shown in SEQ ID NO: 1. Position 771 of the 16S rRNA gene shown in SEQ ID NO: 43 corresponds to position 762 of the 16S rRNA gene shown in SEQ ID NO: 1. Position 785 of the 16S rRNA gene shown in SEQ ID NO: 43 corresponds to position 776 of the 16S rRNA gene shown in SEQ ID NO: 1.
[0105] In one embodiment, a bacterium selected from Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae, and Burkholderia pseudomallei can be identified in a sample based on a SNP at a position corresponding to position 746, 764, 771 or 785 of the 16S rRNA gene set forth in SEQ ID NO: 43 (or position 737, 755, 762 or 776 of the 16S rRNA gene set forth in SEQ ID NO: 1) and high resolution melting curve analysis of the SNPs and their surrounding DNA.
[0106] For example, bacteria selected from among Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei can be identified in a sample based on the above SNP positions and / or high resolution melting curve analysis of the SNPs and their surrounding DNA.
[0107] In another example, yeast organisms or filamentous fungi selected from among Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium spp., Aspergillus fumigatus, and Cryptococcus neoformans can be identified in a sample based on the presence of the SNPs shown in the following table and the DNA melting properties of the SNPs and their surrounding DNA sequences:
[0108] [Table 7]
[0109] In one embodiment, a yeast organism or filamentous fungus selected from Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium spp., Aspergillus fumigatus, and Cryptococcus neoformans can be identified in a sample based on SNPs at positions corresponding to positions 343, 371, 388, 416, and 467 of the 18S rRNA gene set forth in SEQ ID NO:37 and high resolution melting curve analysis of the SNPs and their surrounding DNA.
[0110] For example, yeast organisms or filamentous fungi selected from among Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium spp., Aspergillus fumigatus and Cryptococcus neoformans can be identified in a sample based on the above SNP positions and / or high resolution melting curve analysis of the SNPs and their surrounding DNA.
[0111] In some embodiments, nucleic acid can be extracted from the sample prior to analysis, identification, classification and / or diagnosis. Generally, analysis, identification, classification and / or diagnosis can include amplification of nucleic acid. In some embodiments, analysis, identification, classification and / or diagnosis can further include administering a therapeutic agent, such as an antibiotic, to the subject. In another embodiment, the method of treatment (e.g., as in the third aspect of the invention) can further include determining whether at least one bacteria, yeast organism or filamentous fungus is resistant to the therapeutic agent.
[0112] In one embodiment, any suitable sample can be used in the methods of the invention. Exemplary samples can include sputum, saliva, blood, cerebrospinal fluid or urine samples.
[0113] A probe, tool or reagent may be, without limitation, an oligonucleotide, primer, nucleic acid, polynucleotide, DNA, cDNA, RNA, peptide or polypeptide, which may be, for example, single-stranded or double-stranded, naturally occurring, isolated, purified, chemically modified, recombinant, or synthetic.
[0114] The probe, tool or reagent may be, without limitation, an antibody or other type of molecule or chemical entity capable of specifically binding to, detecting or identifying at least a portion of the 16S rRNA gene or 18S rRNA gene in a sample containing at least one SNP.
[0115] The probes, tools or reagents may be any number or combination of the above, the number and combination depending on the desired result to be achieved - for example, detection of SNPs at the genome level (genotyping) or RNA transcript level.
[0116] The probe, tool or reagent may be isolated. The probe, tool or reagent may be detectably labeled. The detectable label may be included in the amplification reaction. Suitable labels include fluorescent dyes, such as fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, such as 32 P,35 S, 3 H; etc. The label may be a two-step system in which the amplified DNA is conjugated to biotin, hapten, etc., with a high affinity binding partner, such as avidin, specific antibody, etc., where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled to incorporate the label into the amplification product.
[0117] In certain embodiments, at least one probe, tool or reagent is for specific binding, detection or identification of SNPs at the genomic or transcriptional level, preferably at the former.
[0118] In a preferred embodiment, at least one probe, tool or reagent is for specifically binding to, detecting or identifying at least a portion of a 16S rRNA or 18S rRNA gene or gene product in a sample containing at least one SNP set forth in any one of Tables 1 to 7.
[0119] When identifying, partially identifying, or typing bacteria, yeast organisms, or mold fungi, or when identifying, partially identifying, or diagnosing infections with bacteria, yeast organisms, or mold fungi, a single probe (particularly a primer) can be used in each sample, or multiple probes (particularly primers) can be used in each sample (i.e., in one pot). Such probes (particularly primers) can be added to the raw solution resulting from an amplification (such as PCR).
[0120] In one embodiment, at least one probe, tool or reagent can include two primers, each of which hybridizes to at least a portion of a bacterial 16S rRNA gene (or gene product) or at least a portion of an 18S rRNA gene (or gene product) of a yeast organism or filamentous fungus that contains the SNP described above. In another embodiment, at least one probe, tool or reagent can include a probe that hybridizes to at least a portion of a bacterial 16S rRNA gene or gene product or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus that contains the SNP described above.
[0121] In one embodiment, at least one of the probes, tools or reagents comprises an oligonucleotide having (or comprising or consisting of) a nucleotide sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence homology or identity to at least one of SEQ ID NOs: 16-35 and 53-57. The probe, tool or reagent may be a primer. The probe, tool or reagent may comprise an oligonucleotide having a nucleotide sequence as set forth in at least one of SEQ ID NOs: 16-35 and 53-57.
[0122] In one aspect, the present invention provides at least one isolated probe, tool or reagent, wherein the at least one isolated probe, tool or reagent comprises an oligonucleotide having (or comprising or consisting of) a nucleotide sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence homology or identity to at least one of SEQ ID NOs: 16-35 and 53-57. The probe, tool or reagent may be a primer.
[0123] Suitable primers for identifying SNPs in the 16S rRNA sequence shown in SEQ ID NO: 43 (in particular for identifying the SNPs in Table 3) may be as shown in the table below.
[0124] [Table 8]
[0125] Suitable primers for identifying SNPs in the 18S rRNA sequence shown in SEQ ID NO: 37 (in particular for identifying the SNPs in Table 4) may be as shown in the table below.
[0126] [Table 9]
[0127] Any of the features described herein may be combined in any combination with any one or more of the other features described herein within the scope of the present invention.
[0128] The above mainly discusses the use of 16S rRNA and 18S rRNA genes.However, the above is also applicable to 16S rRNA and 18S rRNA and other 16S rRNA and 18S rRNA gene products.Therefore, in some embodiments (where applicable), references to upper and lower 16S rRNA genes and 18S rRNA genes can be replaced with 16S rRNA gene product (or 16S rRNA) and 18S rRNA gene product (or 18S rRNA).
[0129] The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that the prior art forms part of the common general knowledge. [Brief description of the drawings]
[0130] Various embodiments of the present invention will now be described with reference to the following drawings. [Figure 1] Figure 1 shows a CLUSTALW sequence alignment of representative genes encoding 16S rRNA molecules from the following bacterial species: Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes. Variable sequences as determined by the CLUSTALW alignment were extracted. SNPs at positions corresponding to positions 273, 378, 412, 440, 488, 647 and 653 of the 16S rRNA gene from E. coli shown in SEQ ID NO:1 are highlighted along with the corresponding nucleotides in the aligned sequences. [Diagram 2]Figure 2 shows normalized high resolution melting (HRM) curve graphs for the 15 bacterial species tested in Example 1: Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes. [Diagram 3] FIG. 3 shows differential HRM curve graphs for the 15 bacterial species shown in FIG. 2, using Escherichia coli as the baseline. [Figure 4] FIG. 4 shows normalized HRM curve graphs of Staphylococcus aureus and Staphylococcus epidermidis for amplicons containing a SNP at a position corresponding to position 412 of the 16S rRNA gene shown in SEQ ID NO:1. [Diagram 5] FIG. 5 shows differential HRM curve graphs for Staphylococcus aureus and Staphylococcus epidermidis shown in FIG. 4, using S. aureus as the baseline. [Figure 6] FIG. 6 shows normalized HRM curve graphs of Enterococcus faecalis, Enterococcus faecium, Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes for an amplicon containing a SNP at a position corresponding to position 378 of the 16S rRNA gene set forth in SEQ ID NO:1. [Figure 7]FIG. 7 shows differential HRM curve graphs for Enterococcus faecalis, Enterococcus faecium, Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes shown in FIG. 6 using E. faecalis as the baseline. [Figure 8] FIG. 8 shows normalized HRM curve graphs of Escherichia coli, Enterobacter cloacae, Serratia marcescens, Acinetobacter calcoaceticus, Enterobacter aerogenes, Pseudomonas aeruginosa, Klebsiella pneumoniae and Proteus mirabilis for an amplicon containing a SNP at a position corresponding to position 412 of the 16S rRNA gene set forth in SEQ ID NO:1. [Figure 9] FIG. 9 shows differential HRM curve graphs for Escherichia coli, Enterobacter cloacae, Serratia marcescens, Acinetobacter calcoaceticus, Enterobacter aerogenes, Pseudomonas aeruginosa, Klebsiella pneumoniae and Proteus mirabilis shown in FIG. 8 using Escherichia coli as the baseline. [Figure 10] FIG. 10 shows normalized HRM curve graphs of Streptococcus agalactiae, Streptococcus pneumoniae and Streptococcus pyogenes for an amplicon containing a SNP at a position corresponding to position 378 of the 16S rRNA gene shown in SEQ ID NO:1. [Figure 11]FIG. 11 shows the differential HRM curve graphs for Streptococcus agalactiae, Streptococcus pneumoniae and Streptococcus pyogenes shown in FIG. 10 using Streptococcus pneumoniae as the baseline. [Figure 12] FIG. 12 shows normalized HRM curve graphs of Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Enterobacter cloacae and Serratia marcescens for an amplicon containing a SNP at a position corresponding to position 412 of the 16S rRNA gene shown in SEQ ID NO:1. [Figure 13] FIG. 13 shows normalized HRM curve graphs of Streptococcus pneumoniae, Streptococcus agalactiae and Streptococcus pyogenes for amplicons containing a SNP at a position corresponding to position 412 of the 16S rRNA gene shown in SEQ ID NO:1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0131] Key to the sequence table
[0132] SEQ ID NO: 1: 16S rRNA gene of Escherichia coli (Genbank accession NR_102804.1);
[0133] SEQ ID NO:2: 16S rRNA gene of Staphylococcus aureus (Genbank accession NR_075000.1);
[0134] SEQ ID NO:3: 16S rRNA gene of Staphylococcus epidermidis (Genbank accession NR_074995.1);
[0135] SEQ ID NO: 4: 16S rRNA gene of Streptococcus pneumoniae (Genbank accession NR_074564.1);
[0136] SEQ ID NO: 5: 16S rRNA gene of Streptococcus agalactiae (Genbank accession NR_040821.1);
[0137] SEQ ID NO: 6: 16S rRNA gene of Streptococcus pyogenes (Genbank accession NR_074091.1);
[0138] SEQ ID NO: 7: 16S rRNA gene of Enterococcus faecalis (Genbank accession NR_074637.1);
[0139] SEQ ID NO: 8: 16S rRNA gene of Enterococcus faecium (Genbank accession NR_042054.1);
[0140] SEQ ID NO: 9: 16S rRNA gene of Proteus mirabilis (Genbank accession NR_074898.1);
[0141] SEQ ID NO: 10: 16S rRNA gene of Serratia marcescens (Genbank accession NR_041980.1);
[0142] SEQ ID NO: 11: 16S rRNA gene of Enterobacter aerogenes (Genbank accession NR_024643.1);
[0143] SEQ ID NO: 12: 16S rRNA gene of Enterobacter cloacae (Genbank accession NR_028912.1);
[0144] SEQ ID NO: 13: 16S rRNA gene of Klebsiella pneumoniae (Genbank accession NR_036794.1);
[0145] SEQ ID NO: 14: 16S rRNA gene of Pseudomonas aeruginosa (Genbank accession NR_074828.1);
[0146] SEQ ID NO: 15: 16S rRNA gene of Acinetobacter calcoaceticus (Genbank accession AB302132.1);
[0147] SEQ ID NO: 16: forward primer (CCTCTTGCCATCGGATGTG);
[0148] SEQ ID NO: 17: reverse primer (CCAGTGTGGCTGGTCATCCT);
[0149] SEQ ID NO: 18: forward primer (GGGAGGCAGCAGTAGGGAAT);
[0150] SEQ ID NO: 19: forward primer (CCTACGGGAGGCAGCAGTAG);
[0151] SEQ ID NO:20: reverse primer (CGATCCGAAAACCTTCTTCACT);
[0152] SEQ ID NO:21: forward primer (AAGACGGTCTTGCTGTCACTTATAGA);
[0153] SEQ ID NO:22: reverse primer (CTATGCATCGTTGCCTTGGTAA);
[0154] SEQ ID NO:23: forward primer (TGCCGCGTGAATGAAGAA);
[0155] SEQ ID NO:24: forward primer (GCGTGAAGGATGAAGGCTCTA);
[0156] SEQ ID NO:25: forward primer (TGATGAAGGTTTTCGGATCGT);
[0157] SEQ ID NO:26: reverse primer (TGATGTACTATTAACACATCAACCTTCCT);
[0158] SEQ ID NO:27: reverse primer (CCAGTGTGGCTGGTCATCCT);
[0159] SEQ ID NO:28: reverse primer (CGCTCGCCACCTACGTATTAC);
[0160] SEQ ID NO:29: forward primer (GTTGTAAGAGAAGAACGAGTGTGAGAGT);
[0161] SEQ ID NO:30: reverse primer (CGTAGTTAGCCGTCCCTTTCTG);
[0162] SEQ ID NO:31: forward primer (GCGGTTTGTTAAGTCAGATGTGAA);
[0163] SEQ ID NO: 32: forward primer (GGTCTGTCAAGTCGGATGTGAA);
[0164] SEQ ID NO:33: forward primer (TCAACCTGGGAACTCATTCGA);
[0165] SEQ ID NO:34: reverse primer (GGAATTCTACCCCCCTCTACGA);
[0166] SEQ ID NO: 35: reverse primer (GGAATTCTACCCCCCTCTACAAG);
[0167] SEQ ID NO: 36: 18S ribosomal RNA gene of Aspergillus fumigatus strain MJ-X6, complete sequence (GenBank accession HM590663.1);
[0168] SEQ ID NO: 37: 18S ribosomal RNA gene of Candida albicans, complete sequence (GenBank accession AF114470.1);
[0169] SEQ ID NO: 38: 18S ribosomal RNA gene of Candida glabrata strain SZ2, partial sequence (GenBank accession KT229542.1);
[0170] SEQ ID NO: 39: 18S ribosomal RNA gene of Candida parapsilosis, partial sequence (GenBank accession DQ218328.1);
[0171] SEQ ID NO: 40: 18S ribosomal RNA gene of Candida tropicalis, partial sequence (GenBank accession AH009771.2);
[0172] SEQ ID NO: 41: 18S ribosomal RNA rRNA of Cryptococcus neoformans var. grubii H99 (GenBank accession / NCBI reference sequence: XR_001045463.1);
[0173] SEQ ID NO: 42: 18S ribosomal RNA gene of Fusarium sp. strain Z10, partial sequence (GenBank accession MF973465.1);
[0174] SEQ ID NO: 43: 16S ribosomal RNA gene of Bacillus anthracis strain 2000031664, partial sequence (GenBank accession AY138383.1);
[0175] SEQ ID NO: 44: 16S rRNA gene of Burkholderia pseudomallei (GenBank accession AJ131790.1);
[0176] SEQ ID NO: 45: 16S RNA rrn gene of Clostridium botulinum type A (GenBank accession X68185.1);
[0177] SEQ ID NO: 46: 16S RNA rrn gene of Clostridium botulinum type B (GenBank accession X68186.1);
[0178] SEQ ID NO: 47: 16S rRNA rrn gene of Clostridium botulinum type C (GenBank accession X68315.1);
[0179] SEQ ID NO: 48: 16S RNA rrn gene of Clostridium botulinum type D (GenBank accession X68187.1);
[0180] SEQ ID NO: 49: 16S rRNA rrn gene of Clostridium botulinum type G (GenBank accession X68317.1);
[0181] SEQ ID NO: 50: 16S ribosomal RNA of Francisella tularensis strain B-38, partial sequence (GenBank accession / NCBI reference sequence: NR_029362.1);
[0182] SEQ ID NO:51: 16S ribosomal RNA gene of Vibrio cholerae strain DL2, partial sequence (GenBank accession MG062858.1);
[0183] SEQ ID NO: 52: 16S rRNA gene of Yersinia pestis, isolate: SS-Yp-116 (GenBank accession AJ232238.1);
[0184] SEQ ID NO:53: forward primer (CATCCAAGGAAGGCAGCAGGCGCG);
[0185] SEQ ID NO:54: Reverse primer (GTTCAACTACGAGCTTTTTAAC);
[0186] SEQ ID NO:55: reverse primer (GTTCGACTACGAGCTTTTTAAC);
[0187] SEQ ID NO:56: forward primer (GTGTAGCGGTGAAATGCGTAGAG);
[0188] SEQ ID NO: 57: Reverse primer (TCGTTTACCGTGGACTACCAGGG).
[0189] Detailed Description 1.Definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.
[0190] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0191] "Amplification product" or "amplicon" refers to a nucleic acid product generated by a nucleic acid amplification technique.
[0192] As used herein, the term "biological sample" refers to a sample, which may be extracted, untreated, treated, diluted, or concentrated, from a patient or subject. Suitably, the biological sample is selected from any part of the patient's or subject's body, including, but not limited to, hair, skin, nails, tissue, or bodily fluids, such as sputum, saliva, cerebrospinal fluid, urine, and blood.
[0193] In this specification and claims (if any), the word "comprising" and its derivatives including "comprises" and "comprise" include each of the integers specified but do not exclude the inclusion of one or more additional integers.
[0194] As used herein, a "corresponding" nucleic acid position or nucleotide refers to a position or nucleotide present in aligned loci of two or more nucleic acid molecules. Related or variant polynucleotides can be aligned by any method known to those of skill in the art. Such methods generally maximize agreement and include methods such as using manual alignment, as well as using the many alignment programs available (e.g., BLASTN) and others known to those of skill in the art. By aligning the sequences of polynucleotides, one of skill in the art can identify corresponding nucleotides or positions using identical nucleotides as a guide. For example, by aligning the sequence of the gene encoding the 16S rRNA of E. coli (shown in SEQ ID NO:1) with a gene encoding the 16S rRNA from another species, one of skill in the art can identify corresponding positions and nucleotides using conserved nucleotides as a guide.
[0195] "Gene" means a unit of hereditary trait that occupies a specific locus in the genome and consists of transcriptional and / or translational regulatory sequences and / or coding regions and / or untranslated sequences (i.e., introns, 5' and 3' untranslated sequences).
[0196] "Gene product" refers to the product of a gene. For example, the gene product of a 16S rRNA gene includes 16S rRNA. Similarly, the gene product of an 18S rRNA gene includes 18S rRNA. Gene products also include, for example, cDNA sequences derived from rRNA sequences. Gene products can also include products of rRNA where a SNP in an rRNA gene will result in a corresponding change in the product.
[0197] "Homology" refers to the percentage of nucleic acids or amino acids that are identical or that constitute conservative substitutions. Homology can be determined using sequence comparison programs such as GAP (Deveraux et al. 1984), which is incorporated herein by reference. In this method, sequences of similar or substantially different lengths to those cited herein can be compared by inserting gaps into the alignment, such gaps being determined, for example, by the comparison algorithm used by GAP.
[0198] "Hybridization" is used herein to refer to the pairing of complementary nucleotide sequences to produce DNA-DNA or DNA-RNA hybrids. In DNA, A pairs with T and C pairs with G. In RNA, U pairs with A and C pairs with G. In this regard, the terms "match" and "mismatch" as used herein refer to the possibility of hybridization of paired nucleotides in complementary nucleic acid strands. Matching nucleotides, such as the classical AT and GC base pairs noted above, hybridize efficiently. Mismatches are other combinations of nucleotides that do not hybridize efficiently. Nucleotide symbols are shown in the following table:
[0199] [Table 10]
[0200] "Isolated" means material that is substantially or effectively free from components which normally accompany it in its natural state.
[0201] The term "oligonucleotide" as used herein refers to a polymer composed of a number of nucleotide residues (deoxynucleotides or ribonucleotides, or related structural variants or synthetic analogs thereof) linked through phosphodiester bonds (or related structural variants or synthetic analogs thereof). Thus, the term "oligonucleotide" generally refers to a nucleotide polymer in which the nucleotide residues and the linkages between them are naturally occurring, but it is understood that the term also includes within its scope various analogs, including but not limited to peptide nucleic acid (PNA), phosphoramidates, phosphorothioates, methylphosphonates, 2-O-methyl ribonucleic acid, and the like. The exact size of the molecule can vary depending on the particular application. Oligonucleotides are generally fairly short, generally about 10 to 30 nucleotide residues in length, but the term can refer to molecules of any length, although the terms "polynucleotide" or "nucleic acid" are commonly used for large oligonucleotides.
[0202] The terms "patient" and "subject" are used interchangeably and refer to human or other mammalian patients and subjects, including any individual who is examined or treated using the method of the present invention. However, it is understood that "patient" does not imply the presence of symptoms. Suitable mammals within the scope of the present invention include, but are not limited to, primates, farm animals (e.g., sheep, cows, horses, donkeys, pigs), laboratory animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and game animals (e.g., koalas, bears, wild cats, wild dogs, wolves, dingoes, foxes, etc.).
[0203] The term "polymorphism" as used herein refers to the difference in the nucleotide or amino acid sequence of a given region when compared with the nucleotide or amino acid sequence of the homologous region of another individual, particularly the difference in the nucleotide or amino acid sequence of a given region that differs between individuals of the same species. Polymorphisms are generally defined with respect to a reference sequence. Polymorphisms include single nucleotide differences, differences in multiple nucleotides, and insertions, inversions, and deletions of single or multiple nucleotides; and single amino acid differences, differences in the sequence of multiple amino acids, and insertions, inversions, and deletions of single or multiple amino acids. A "polymorphic site" is the locus where mutations occur. It should be understood that polymorphisms exist in nucleic acid sequences, and when referring to the presence of a particular base or bases at a polymorphic site, the invention encompasses the complementary base or bases on the complementary strand of the site.
[0204] As used herein, the term "polynucleotide" or "nucleic acid" refers to mRNA, RNA, rRNA, cRNA, cDNA, or DNA. The term generally refers to oligonucleotides greater than 30 nucleotide residues in length.
[0205] "Primer" means an oligonucleotide that, when paired with a strand of DNA, is capable of initiating synthesis of a primer extension product in the presence of a suitable polymerization agent. Primers are preferably single-stranded for maximum efficiency of amplification, but may alternatively be double-stranded. A primer must be sufficiently long to prime the synthesis of an extension product in the presence of a polymerization agent. The length of a primer depends on many factors, including the application, temperature used, template reaction conditions, other reagents, and source of primer. For example, depending on the complexity of the target sequence, an oligonucleotide primer typically contains 15-35 or more nucleotide residues, although it can contain fewer nucleotide residues. A primer may be a large polynucleotide, for example, from about 200 nucleotides to several kilobases or more. A primer can be selected to be "substantially complementary" to a sequence on the template to which it is designed to hybridize and serve as a site for initiation of synthesis. "Substantially complementary" means that the primer is sufficiently complementary to hybridize with a target polynucleotide. In some embodiments, the primer does not contain mismatches with the template to which it is designed to hybridize, but this is not required. For example, a non-complementary nucleotide residue can be attached to the 5' end of the primer, while the remainder of the primer sequence is complementary to the template. Alternatively, a non-complementary nucleotide residue or stretches of non-complementary nucleotide residues can be interspersed throughout the primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to hybridize therewith and thereby form a template for synthesis of an extension product of the primer.
[0206] "Probe" refers to a molecule that binds to a specific sequence or subsequence or other portion of another molecule. Unless otherwise indicated, the term "probe" generally refers to a polynucleotide probe that binds to another polynucleotide, often referred to as a "target polynucleotide", through complementary base pairing. A probe can bind to a target polynucleotide that lacks complete sequence complementarity with the probe, depending on the stringency of the hybridization conditions. A probe can be directly or indirectly labeled.
[0207] As used herein, the term "sepsis" is used according to its ordinary meaning in clinical medicine and includes systemic and / or blood-borne infections, such as bacterial infections.
[0208] The term "sepsis-associated bacteria" refers to bacteria that have been identified as capable of causing sepsis in a subject or that have been identified in the blood of a septic subject. Thus, "mammalian (e.g., human) sepsis-associated bacteria" refers to bacteria that have been identified as capable of causing sepsis in a mammalian (e.g., human) subject or that have been identified in the blood of a septic mammalian (e.g., human) subject. Examples of mammalian (e.g., human) sepsis-associated bacteria include Acinetobacter baumannii, Actinobacillus hominis, Actinomyces massiliensis, Aeromonas hydrophila, Bacillus anthracis, Bacteroides fragilis, Brucella abortus, Burkholderia cepacia, Campylobacter coli, Campylobacter fetus, Campylobacter jejuni, Campylobacter lari, Cardiobacterium valvarum, Chlamydia trachomatis, Chlamydophila abortus, Chlamydophila pneumoniae, Citrobacter freundii, Clostridium difficile, Clostridium perfringens, Corynebacterium diphtheriae, Corynebacterium jeikeium, Corynebacterium urealyticum, Dermatophilus congolensis, Edwardsiella tarda, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Escherichia coli, Eubacterium desmolans, Flavobacterium ceti, Haemophilus ducreyi, Haemophilus influenzae, Haemophilus parahaemolyticus, Haemophilusparainfluenzae, Helicobacter cinaedi, Helicobacter pylori, Klebsiella oxytoca, Klebsiella pneumonia, Lactobacillus intestinalis, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Micrococcus luteus, Mobiluncus curtisii, Moraxella catarrhalis, Morganella morganii, Mycobacterium tuberculosis, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroids, Nocardia brasiliensis, Pasteurella multocida, Peptostreptococcus stomatis, Porphyromonas gingivalis, Prevotella buccae, Prevotella intermedia, Prevotella melaninogenica, Proteus mirabilis, Providencia alcalifaciens, Pseudomonas aeruginosa, Rhodococcus equi, Salmonella enterica, Serratia marcescens, Shigella dysenteriae, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, Stenotrophomonas maltophila, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus bovis, Streptococcus constellatus, Streptococcus dysgalactiae, Streptococcusintermedins, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus sanguinis, Streptococcus sobrinus, Streptomyces anulatus, Streptomyces somaliensis, Veillonella atypica, Veillonella denticariosi, Veillonella dispar, Veillonella parvula, Veillonella rogosae, Vibrio cholerae, Yersinia enterocolitica and Yersinia pestis.
[0209] As used herein, "sepsis" is defined as SIRS with a presumed or confirmed infectious process. Confirmation of an infectious process can be determined using microbiological culture or isolation of an infectious agent. From an immunological perspective, sepsis can be viewed as a systemic response to a microbial or systemic infection.
[0210] As used herein, "systemic inflammatory response syndrome (SIRS)" refers to a clinical response resulting from a non-specific insult that has two or more of the following measurable clinical characteristics: body temperature above 38°C or below 36°C, heart rate above 90 beats per minute, respiratory rate above 20 breaths per minute, and blood pressure above 1 mmHg. 3 More than 12,000 per mm 3 A white blood cell count (total white blood cells) of less than 4,000 per 100, or a band neutrophil percentage of more than 10%. From an immunological perspective, it can be seen as representing a systemic response to injury (e.g., major surgery) or systemic inflammation. Thus, as used herein, "inSIRS (in infection-negative SIRS)" includes the clinical responses described above, but in the absence of a discernible infectious process.
[0211] The term "sequence identity" as used herein refers to the degree to which sequences are identical on a nucleotide or amino acid basis over a comparison window.Therefore, "sequence identity percentage" is calculated by comparing two optimally aligned sequences over a comparison window, determining the number of positions where the same nucleic acid base (e.g., A, T, C, G) exists in both sequences to give the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., window size), and multiplying the result by 100 to give the sequence identity percentage (% sequence identity).
[0212] As used herein, the term single nucleotide polymorphism (SNP) refers to a nucleotide sequence variation that occurs when a single nucleotide (A, T, C, or G) in a genomic sequence is altered (e.g., through a substitution, addition, or deletion). SNPs can occur in both coding (gene) and non-coding regions of a genome, such as the genome of a prokaryotic or eukaryotic microorganism.
[0213] As used herein, the terms "treatment", "treating" and the like refer to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic in that it completely or partially prevents an infection, condition or its symptoms, and / or it may be therapeutic in that it partially or completely cures an infection, condition and / or deleterious effects caused by the infection or condition. As used herein, "treatment" encompasses any treatment of an infection or condition in a mammal (e.g., a human), including (a) inhibiting the infection or condition, i.e., inhibiting its development; and (b) relieving the infection or condition, i.e., causing regression of the infection or condition.
[0214] 2. Polymorphisms of the Invention The present invention is based in part on the determination that SNPs in the 16S rRNA gene (and thus within the 16S rRNA molecule) of bacteria can be used to identify individual species of bacteria and / or to classify bacteria based on genus or as Gram-positive or Gram-negative. The present invention is also based in part on the determination that SNPs in the 18S rRNA gene (and thus within the 18S rRNA molecule) can be used to identify, partially identify or classify yeast organisms or filamentous fungi.
[0215] 2.1 Bacterial classification using SNPs in 16S rRNA The present invention provides methods for classifying bacterial species based on genus, as well as methods for determining the gram status of bacteria in a sample, i.e., whether the bacteria is gram positive or gram negative.
[0216] As demonstrated herein, polymorphisms at nucleotide positions in the gene encoding 16S rRNA (and thus the 16S rRNA molecule itself) corresponding to positions 273 and 653 of the 16S rRNA gene of E. coli as set forth in SEQ ID NO:1 can be used to determine the Gram status of selected bacterial species in a sample, particularly including mammalian (e.g., human) pathogens, including the most commonly found bacterial species isolated by blood culture (Karlowsky et al. 2004).
[0217] Most particularly, and as shown in FIG. 1, the present invention provides a method for classifying bacterial species selected from among: Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes.
[0218] For example, a method for determining the Gram status of one of the bacteria in a sample set forth in the paragraph above includes analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or the 16S rRNA or a DNA copy thereof) at positions corresponding to positions 273 and 653 of the 16S rRNA gene set forth in SEQ ID NO:1, where an A at position 273 and a T at position 653 indicate that the bacteria in the sample is Gram positive.
[0219] Another method for determining the Gram status of one of the above bacteria in a sample includes analyzing nucleic acid from a sample for a SNP in the 16S rRNA gene (or the 16S rRNA or a DNA copy thereof) at position 440 of the 16S rRNA gene set forth in SEQ ID NO:1, where a T at position 440 indicates that the bacterium in the sample is Gram positive.
[0220] A method for classifying at least one of the above bacteria in a sample as belonging to a particular genus comprises analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or the 16S rRNA or a DNA copy thereof) at positions corresponding to positions 412 and 647 of the 16S rRNA gene as set forth in SEQ ID NO:1, where: a T at position 412 indicates that the bacterium belongs to the genus Staphylococcus; or a G at position 647 indicates that the bacterium belongs to the genus Enterococcus.
[0221] 2.2 Identification of bacteria using 16S rRNA SNPs and yeast organisms and filamentous fungi using 18S rRNA The present invention also provides a method for identifying bacteria in a sample.
[0222] As demonstrated herein, polymorphisms at nucleotide positions in the gene encoding 16S rRNA (and thus the 16S rRNA molecule itself) corresponding to any one of positions 273, 378, 412, 440, 488, 647, and 653 of the 16S rRNA gene of E. coli as set forth in SEQ ID NO:1 can be used to identify bacteria in a sample, particularly including mammalian (e.g., human) pathogens, including the most commonly found bacterial species isolated by blood culture (Karlowsky et al. 2004).
[0223] In one embodiment, and as shown in FIG. 1, the present invention provides a method for identifying a bacterium selected from among the following: Acinetobacter calcoaceticus; Enterobacter aerogenes; Enterobacter cloacae; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes.
[0224] General rules for identifying the above bacterial species in a sample using the above SNPs are shown in Table 1 and / or Table 5.
[0225] From the above bacteria, the bacterium Enterobacter cloacae can be identified in a sample by analyzing nucleic acid from a sample for a SNP in the 16S rRNA gene (or the 16S rRNA or a DNA copy thereof) at a position corresponding to position 653 of the 16S rRNA gene set forth in SEQ ID NO:1, where a G at position 653 indicates that the bacterium is Enterobacter cloacae.
[0226] From the above bacteria, bacteria selected from Streptococcus agalactiae, Streptococcus pneumoniae and Streptococcus pyogenes can be identified in a sample by analysing nucleic acid from a sample for SNPs in the 16S rRNA gene (or the 16S rRNA or a DNA copy thereof) at positions corresponding to positions 378 and 488 of the 16S rRNA gene as set forth in SEQ ID NO:1, where: an A at position 378 and a T at position 488 indicates that the bacterium is Streptococcus pneumoniae; an A at positions 378 and 488 indicates that the bacterium is Streptococcus agalactiae; a G at position 378 and an A at position 488 indicates that the bacterium is Streptococcus pyogenes.
[0227] From the above bacteria, the method can identify in a sample a bacterium selected from Acinetobacter calcoaceticus; Enterobacter cloacae; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or the 16S rRNA or DNA copy thereof) at positions corresponding to positions 273, 378, 412, 440, 488, 647 and 653 of the 16S rRNA gene set forth in SEQ ID NO:1, where: A at positions 273, 440 and 647 indicates that the bacterium is Acinetobacter calcoaceticus; G at position 653 indicates that the bacterium is Enterobacter cloacae; T at position 273 and 653 indicates that the bacterium is E. coli; T at position 273, C at positions 488 and 647, and A at position 653 indicates that the bacterium is Klebsiella pneumoniae; C at positions 440 and 488, and T at position 647 indicate that the bacterium is Proteus mirabilis; A at position 440 and T at position 647 indicate that the bacterium is Pseudomonas aeruginosa; A at positions 378, 488, and 647 indicate that the bacterium is Streptococcus agalactiae; T at positions 488 and 647 indicate that the bacterium is Streptococcus pneumoniae; G at position 378 and A at positions 488 and 647 indicate that the bacterium is Streptococcus pyogenes.
[0228] In addition to the above, the method of the present invention can also be used to identify the presence of the following bacteria in a sample: Staphylococcus aureus; S. epidermidis; Enterococcus faecalis; Enterococcus faecium; Serratia marcescens and Enterobacter aerogenes. The method also includes analyzing nucleic acid from a sample for SNPs in the 16S rRNA gene (or a DNA copy thereof) at positions corresponding to any one of positions 273, 378, 412, 440, 488, 647 and 653 of the 16S rRNA gene as set forth in SEQ ID NO:1, where: a T at position 412 indicates that the sample contains the bacteria Staphylococcus aureus and / or S. epidermidis; a G at position 647 indicates that the sample contains the bacteria Enterococcus faecalis and / or Enterococcus faecium; and a C at positions 440 and 647 and a T at position 488 indicates that the sample contains the bacteria Serratia marcescens and / or Enterobacter aerogenes.
[0229] In addition to the above, the method of the present invention can also be used to identify each of Staphylococcus aureus; S. epidermidis; Enterococcus faecalis; Enterococcus faecium; Serratia marcescens and Enterobacter aerogenes in a sample. The method further comprises analyzing the nucleic acid from the sample by high-resolution melting analysis (see 3.8 below). High-resolution melting analysis allows nucleic acid sequences originating from different bacteria but containing the same SNP(s) to be distinguished from each other based on mutations in the surrounding nucleotide bases.
[0230] In another embodiment, the present invention provides a method for identifying bacteria selected from among Escherichia coli, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Proteus mirabilis, Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter calcoaceticus, Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus, Clostridium perfringens, Corynebacterium jeikeium, Bacteroides fragilis, Neisseria meningitidis, Haemophilus influenzae, Serratia marcescens, Salmonella sp. and Staphylococcus epidermidis. General rules for identifying the above bacterial species in a sample using the above SNPs are shown in Table 2.
[0231] Similarly, as demonstrated herein, polymorphisms at nucleotide positions in the gene encoding 16S rRNA (and thus the rRNA molecule itself) corresponding to positions 746, 764, 771 or 785 of the 16S rRNA gene of Bacillus anthracis set forth in SEQ ID NO:43 (or positions 737, 755, 762 or 776 of the 16S rRNA gene set forth in SEQ ID NO:1) can be used to identify bacteria in a sample, particularly including mammalian (e.g., human) pathogens (including pathogens known as security-sensitive bioagents).
[0232] In one embodiment, a method is provided for identifying a bacterium selected from among Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae, and Burkholderia pseudomallei.
[0233] General rules for identifying the above bacterial species in a sample using the above SNPs are shown in Tables 3 and / or 6.
[0234] From the above bacteria, the bacterium Bacillus anthracis can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or 16S rRNA or a DNA copy thereof) of SEQ ID NO: 43, where T at position 746, A at position 764, C at position 771 and G at position 785 indicate that the bacterium is Bacillus anthracis.
[0235] From the above bacteria, bacteria selected from Clostridium botulinum type A or Clostridium botulinum type B can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene of SEQ ID NO: 43 (or the 16S rRNA or a DNA copy thereof), where T at position 746, G at position 764, C at position 771 and T at position 785 indicate that the bacterium is Clostridium botulinum type A or Clostridium botulinum type B.
[0236] From the above bacteria, the bacteria Clostridium botulinum type C can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene of SEQ ID NO: 43 (or the 16S rRNA or a DNA copy thereof), where T at position 746, A at position 764, T at position 771 and T at position 785 indicate that the bacterium is Clostridium botulinum type C.
[0237] From the above bacteria, the bacteria Clostridium botulinum type D can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or 16S rRNA or a DNA copy thereof) of SEQ ID NO: 43, where C at position 746, A at position 764, T at position 771 and T at position 785 indicate that the bacterium is Clostridium botulinum type D.
[0238] From the above bacteria, the bacteria Clostridium botulinum type G can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene of SEQ ID NO: 43 (or the 16S rRNA or a DNA copy thereof), where T at position 746, G at position 764, C at position 771 and G at position 785 indicate that the bacterium is Clostridium botulinum type G.
[0239] From the above bacteria, the bacterium Yersinia pestis can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or 16S rRNA or a DNA copy thereof) of SEQ ID NO: 43, where a C at position 746, a G at position 764, a T at position 771 and a G at position 785 indicate that the bacterium is Yersinia pestis.
[0240] From the above bacteria, the bacterium Francisella tularensis can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or 16S rRNA or a DNA copy thereof) of SEQ ID NO: 43, where T at position 746, A at position 764, G at position 771 and G at position 785 indicate that the bacterium is Francisella tularensis.
[0241] From the above bacteria, the bacterium Vibrio cholerae can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or 16S rRNA or a DNA copy thereof) of SEQ ID NO: 43, where a C at position 746, an A at position 764, a T at position 771 and a G at position 785 indicate that the bacterium is Vibrio cholerae.
[0242] From the above bacteria, the bacterium Burkholderia pseudomallei can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 16S rRNA gene (or 16S rRNA or a DNA copy thereof) of SEQ ID NO: 43, where C at position 746, G at position 764, C at position 771 and G at position 785 indicate that the bacterium is Burkholderia pseudomallei.
[0243] In addition to the above, the method of the present invention may also be used to identify each of Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei in a sample. The method includes further analyzing the nucleic acid from the sample by high resolution melting analysis (see 3.8 below).
[0244] Similarly, as demonstrated herein, polymorphisms at nucleotide positions in the gene encoding 18S rRNA (and thus the rRNA molecule itself) corresponding to positions 343, 371, 388, 416 and 467 of the 18S rRNA gene of Candida albicans set forth in SEQ ID NO:37 can be used to identify bacteria in a sample, particularly including mammalian (e.g., human) pathogens.
[0245] In one embodiment, a method is provided for identifying a yeast organism or a filamentous fungus selected from among: Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium spp., Aspergillus fumigatus, and Cryptococcus neoformans.
[0246] General rules for identifying the above bacterial species in a sample using the above SNPs are shown in Tables 4 and / or 7.
[0247] From the yeast organisms or filamentous fungi described above, the yeast organism Candida albicans can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 18S rRNA gene (or 18S rRNA or a DNA copy thereof) of SEQ ID NO: 37, where C at position 343, A at position 371, T at position 388, G at position 416 and G at position 467 indicate that the yeast organism is Candida albicans.
[0248] From the yeast organisms or filamentous fungi described above, the yeast organism Candida tropicalis can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 18S rRNA gene (or 18S rRNA or a DNA copy thereof) of SEQ ID NO: 37, where C at position 343, A at position 371, C at position 388, G at position 416 and C at position 467 indicate that the yeast organism is Candida tropicalis.
[0249] From the yeast organisms or filamentous fungi described above, the yeast organism Candida parapsilosis can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 18S rRNA gene (or 18S rRNA or a DNA copy thereof) of SEQ ID NO: 37, where C at position 343, A at position 371, C at position 388, G at position 416 and G at position 467 indicate that the yeast organism is Candida parapsilosis.
[0250] From the yeast organisms or filamentous fungi described above, the yeast organism Candida glabrata can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 18S rRNA gene (or 18S rRNA or a DNA copy thereof) of SEQ ID NO: 37, where T at position 343, A at position 371, C at position 388, G at position 416 and G at position 467 indicate that the yeast organism is Candida glabrata.
[0251] From the yeast organisms or filamentous fungi described above, the yeast organism Cryptococcus neoformans can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 18S rRNA gene (or 18S rRNA or a DNA copy thereof) of SEQ ID NO: 37, where C at position 343, A at position 371, T at position 388, T at position 416 and G at position 467 indicate that the yeast organism is Cryptococcus neoformans.
[0252] From the yeast organisms or filamentous fungi described above, filamentous fungi Fusarium spp. can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 18S rRNA gene of SEQ ID NO:37 (or the 18S rRNA or a DNA copy thereof), where C at position 343, C at position 371, T at position 388, T at position 416 and G at position 467 indicate that the filamentous fungus is Fusarium spp.
[0253] From the yeast organisms or filamentous fungi described above, the filamentous fungus Aspergillus fumigatus can be identified in a sample by analyzing nucleic acid from the sample for SNPs in the 18S rRNA gene of SEQ ID NO:37 (or the 18S rRNA or a DNA copy thereof), where a C at position 343, a C at position 371, a T at position 388, a C at position 416 and a G at position 467 indicate that the filamentous fungus is Aspergillus fumigatus.
[0254] In addition to the above, the method of the present invention can also be used to identify each of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium spp., Aspergillus fumigatus and Cryptococcus neoformans in a sample. The method includes further analyzing nucleic acid from the sample by high resolution melting analysis (see 3.8 below).
[0255] 3. Screening for specific polymorphisms to identify and / or classify bacteria, yeast organisms and filamentous fungi according to the present invention The steps / techniques of isolating a biological sample from a subject, processing the biological sample, extraction of genomic DNA, extraction of RNA, DNA detection and characterization, RNA detection and characterization, DNA sequencing, analysis of DNA sequences, SNP genotyping studies, RNA location and identification, RNA profiling and RNA screening, RNA sequencing, analysis of RNA sequences may be carried out in any suitable manner.
[0256] Any method known in the art for detecting one or more SNPs can be used in the methods described herein to classify and / or identify bacterial species in a sample. In certain embodiments, the method facilitates narrowing down or in some cases confirming one bacterial species (or yeast organism or filamentous fungal species) instead of another. Numerous methods are known in the art for determining the presence of a nucleotide at a specific position corresponding to a single nucleotide polymorphism in a sample. Various tools for detecting polymorphisms include, but are not limited to, DNA sequencing, scanning techniques, hybridization-based techniques, extension-based analysis, high-resolution melting analysis, integration-based techniques, restriction enzyme-based analysis, and ligation-based techniques.
[0257] The method according to the invention can identify the polymorphisms described herein in the 16S rRNA or 18S rRNA gene, in the 16S rRNA or 18S rRNA molecule, or in a DNA copy thereof, for either strand. In some cases, the method of detecting the polymorphism utilizes a first step of amplification, which may be from the 16S rRNA or 18S rRNA gene, or from a DNA copy of the 16S rRNA or 18S rRNA molecule.
[0258] The nucleic acid may be from a biological sample from a subject, or from an environmental sample, such as air, soil or water samples, filtrate, food or manufactured products, or from a surface, such as swap from a medical instrument or work surface. The subject may be a human subject or a non-human subject, such as a mammalian subject, such as a primate, a livestock animal (e.g., sheep, cow, horse, donkey, pig), a laboratory animal (e.g., rabbit, mouse, rat, guinea pig, hamster), a companion animal (e.g., cat, dog) and a game animal (e.g., koala, bear, wild cat, wild dog, wolf, dingo, fox, etc.). The biological sample from a subject may be from any part of the subject's body, including, but not limited to, a bodily fluid, such as blood, saliva, sputum, urine, cerebrospinal fluid, feces, a cell, a tissue, or a biopsy. In another example, the nucleic acid is obtained from a cultured cell.
[0259] The nucleic acid analyzed by the method of the present invention can be analyzed while in the sample, or it can be first extracted, e.g., isolated, from the sample before analysis. Any method for isolating nucleic acid from a sample can be used in the method of the present invention, and such methods are well known to those skilled in the art. The extracted nucleic acid can include DNA and / or RNA (including mRNA or rRNA). In some cases, the method can include an additional step of reverse transcription before analysis. Thus, the analyzed nucleic acid can include 16S rRNA gene, 18S rRNA gene, 16S rRNA, 18S rRNA, DNA copy of 16S rRNA or 18S rRNA, or any combination thereof. The nucleic acid can also contain a portion of 16S rRNA gene, 18S rRNA gene, 16S rRNA, 18S rRNA, or DNA copy of 16S rRNA or 18S rRNA, providing the portion containing the nucleic acid position analyzed for SNP.
[0260] In some cases, the method includes nucleic acid amplification.In such cases, suitable nucleic acid amplification techniques are well known to those skilled in the art, and include polymerase chain reaction (PCR), for example described in Ausubel et al., Current Protocols in Molecular Biology (John Wiley & Sons, Inc. 1994-1998), strand displacement amplification (SDA), for example described in U.S. Pat. No. 5,422,252, rolling circle replication (RCR), for example described in Liu et al. (1996) and WO 92 / 01813 and WO 97 / 19193, nucleic acid sequence-based amplification (NASBA), for example described in Sooknanan et al., (1994), ligase chain reaction (LCR), single sequence repeat analysis (SSR), branched DNA amplification assay (b-DNA), transcription amplification and autonomous sequence replication, and Q-beta replicase amplification, for example described in Tyagi et al. (1996).
[0261] Such methods can utilize one or more oligonucleotide probes or primers, including, for example, an amplification primer pair that selectively hybridizes to a target polynucleotide containing one or more SNPs.The oligonucleotide probe useful in carrying out the method of the present invention can include, for example, an oligonucleotide that is complementary to and spans a portion of the target polynucleotide that includes the position of the SNP, and the presence of a specific nucleotide of the polymorphic site (i.e., SNP) is detected by the presence or absence of selective hybridization of the probe.Such methods can further include contacting the target polynucleotide and the hybridized oligonucleotide with an endonuclease, and detecting the presence or absence of the cleavage product of the probe by the presence or absence of the nucleotide of the polymorphic site that is complementary to the corresponding nucleotide of the probe.
[0262] Primers can be produced using any convenient synthesis method. Examples of such methods can be found in "Protocols for Oligonucleotides and Analogues; Synthesis and Properties", Methods in Molecular Biology Series, Volume 20, Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7, 1993. Primers can also be labeled to facilitate detection.
[0263] Any method useful for the detection of SNPs can be used in the present invention, and many different methods for SNP genotyping are known in the art (for reviews, see Syvanen, AC (2001); Kim, S. and Misra, A., (2007)). Such methods can consist of the use of three consecutive steps including "reaction" (e.g., hybridization, ligation, extension and cleavage) followed by "separation" (e.g., solid-phase microtiter plate, microparticles or arrays, gel electrophoresis, solution phase homogeneous or semi-homogeneous). No single SNP genotyping method is ideal for all applications, and it is within the skill of the artisan to determine the most suitable method taking into account various parameters, such as sample size and number of SNPs to be analyzed.
[0264] Exemplary techniques that are particularly useful for clinical use and rely on interrogating a small number of SNPs are rapid, sensitive (through amplification of nucleic acids in a sample), single-step, with real-time measurement output, capable of being multiplexed and automated, relatively inexpensive, and accurate; examples include, but are not limited to, the TaqMan® assay (5' nuclease assay, Applied Biosystems), high-resolution melting analysis, molecular beacon probes such as LUX® (Invitrogen) or Scorpion® probes (Sigma Aldrich), and template directed dye incorporation (TDI, Perkin Elmer).
[0265] For example, TaqMan® (Applied Biosystems) uses a combination of hybridization with allele-specific probes, homogeneous solution phase and fluorescence resonance energy transfer. The TaqMan® assay relies on forward and reverse primers to amplify nucleic acids and Taq DNA polymerase's 5'-nuclease activity to degrade a labeled probe designed to bind across the SNP site(s). The reaction, separation and detection are all performed simultaneously, and the results can be read in real time as the reaction progresses. Although such an approach does not lend itself to analyzing a large number of SNPs simultaneously, it is particularly suitable for interrogating a small number of SNPs quickly, sensitively and accurately at a reasonable cost.
[0266] Any method known in the art for detecting one or more SNPs to classify and / or identify bacteria and / or bacteria in a sample can be used in the methods described herein, although some methods may be more suitable than others. Non-limiting examples of such methods are described below.
[0267] 3.1 Nucleic acid sequencing technology In some embodiments, the polymorphism is identified by nucleic acid sequencing techniques. Specifically, the amplification product across the SNP locus can be sequenced using traditional sequencing methods (e.g., the "dideoxy-mediated chain termination method," also known as the "Sanger method" (Sanger, F., et al. (1975), and the "chemical degradation method," also known as the "Maxam-Gilbert method" (Maxam, AM, et al., 1977), both references are incorporated herein by reference to determine the presence of a nucleotide at the SNP locus.
[0268] Boyce-Jacino et al., U.S. Patent No. 6,294,336, provide a solid-phase sequencing method for determining the sequence of a nucleic acid molecule (DNA or RNA) by utilizing a primer that selectively binds to a polynucleotide target at a site where the SNP is the 3'-most nucleotide that selectively binds to the polynucleotide target. Other sequencing techniques such as denaturing high pressure liquid chromatography or mass spectrometry can also be used.
[0269] In another illustrative example, the sequencing method includes a technology known as Pyrosequencing™. This approach is based on the generation of pyrophosphate whenever a deoxynucleotide is incorporated during DNA polymerization. The generation of pyrophosphate is coupled to a luciferase-catalyzed reaction, resulting in light emission if the specific deoxynucleotide added is incorporated, giving a quantitative and characteristic pyrogram. Sample processing includes PCR amplification with biotinylated primers, isolation of the biotinylated single-stranded amplicons on streptavidin-coated beads (or other solid phase), and annealing of the sequencing primer. The sample is then analyzed by Pyrosequence™, which adds several enzymes and substrates required for the indicator reaction, including sulfurylase and luciferase, as well as pyrase for the degradation of unincorporated molecules. The sample is then interrogated by the addition of four deoxynucleotides. The light emission can be detected with a charge-coupled device (CCD) camera and is proportional to the number of nucleotides incorporated. Results are assigned automatically through pattern recognition.
[0270] Alternatively, the method of the present invention can use "microsequencing" methods to identify the presence of nucleotides at polymorphic sites in nucleic acids. Microsequencing methods determine the identity of only a single nucleotide at a "predetermined" site. Such methods are particularly useful in determining the presence and identity of polymorphisms in target polynucleotides. Such microsequencing methods, as well as other methods for determining the presence of nucleotides at polymorphic sites, are discussed in U.S. Patent No. 6,294,336, which is incorporated herein by reference.
[0271] Microsequencing methods include the Genetic Bit Analysis™ method disclosed in WO 92 / 15712. Additional primer-guided nucleotide incorporation procedures for examining polymorphic sites in DNA have also been described (Komher, JS, et al., 1989; Sokolov, BP, 1990; Syvanen, AC, et al., 1990; Kuppuswamy, MN, et al., 1991; Prezant, TR, et al. 1992; Ugozzoli, L., et al., 1992; Nyren, P., et al. 1993; and WO 89 / 10414). These methods differ from Genetic Bit Analysis™ in that they all rely on the incorporation of labeled deoxynucleotides to distinguish the bases at polymorphic sites. In such a format, signal is proportional to the number of deoxynucleotides incorporated, so that polymorphisms present in a run of the same nucleotides can result in a signal proportional to the length of the run (Syvanen, AC, et al. 1993).
[0272] Further microsequencing methods are provided by U.S. Patent No. 4,656,127 and French Patent No. 2,650,840 (WO 91 / 02087), which include solution-based methods for determining the identity of the nucleotide at a polymorphic site. As in the U.S. patent method, a primer is used that is complementary to the allelic sequence immediately 3' to the polymorphic site.
[0273] In another illustrative example, US Patent No. 5,002,867 describes, for example, a method for determining a nucleic acid sequence through hybridization with a mixture of oligonucleotide probes. With such a method, the sequence of a target polynucleotide is determined by allowing the target to sequentially hybridize with a set of probes that have an invariant nucleotide at one position and a variant nucleotide at another position. The method determines the nucleotide sequence of the target by hybridizing the target with a set of probes and then determining the number of sites at which at least one member of the set is able to hybridize to the target (i.e., the number of matches). This procedure is generally repeated until each member of the set of probes has been tested.
[0274] Alternatively, the template-directed dye-terminator incorporation assay with fluorescence polarization detection (FP-TDI) assay (Chen et al. 1999) is a version of the primer extension assay, also called minisequencing or single-base extension assay (Syvanen, AC, et al., 1990). Primer extension assays are capable of detecting SNPs. The DNA sequencing protocol identifies the nature of the single base immediately 3' of the SNP-specific sequencing primer that is annealed to the target DNA immediately upstream from the polymorphic site. In the presence of DNA polymerase and appropriate dideoxyribonucleoside triphosphates (ddNTPs), the primer is specifically extended by one base, as dictated by the target DNA sequence at the polymorphic site. By determining which ddNTP is incorporated, the allele(s) present in the target DNA can be inferred.
[0275] 3.2 Polymorphic hybridization-based techniques Hybridization techniques for detecting polymorphisms in nucleotide sequences can include, but are not limited to, TaqMan® assays (Applied Biosystems), dot blots, reverse dot blots, multiplex allele-specific diagnostic assays (MASDA), dynamic allele-specific hybridization (DASH) (Jobs et al. 2003), molecular beacons and Southern blots.
[0276] The TaqMan® assay for identifying SNPs in nucleotide sequences (also known as the 5' nuclease assay or 5' digestion assay) is based on the nuclease activity of Taq polymerase, which displaces and cleaves oligonucleotide probes hybridized to target DNA to generate a fluorescent signal. A TaqMan® probe specific for a particular SNP is required, each probe having a different fluorescent dye attached to the 5' end and a quencher attached to the 3' end. When the probe is intact, the quencher interacts with the fluorophores by fluorescence resonance energy transfer (FRET), quenching their fluorescence. During the PCT annealing step, the TaqMan® probe hybridizes to the target DNA. In the extension step, the fluorescent dye is cleaved by the nuclease activity of Taq polymerase, leading to an increase in fluorescence by the reporter dye. Mismatched probes are displaced without fragmentation. The genotype of the sample is determined by measuring the signal intensity of the two different dyes.
[0277] Another useful SNP identification method includes DASH (Dynamic Allele-Specific Hybridization), which involves the kinetic tracking of probes (oligonucleotides) to target (PCR product) hybridization as the reaction temperature is steadily increased to identify polymorphisms (Prince, JA, et al. 2001).
[0278] In some embodiments, multiplex allele-specific diagnostic assays (MASDA) can be used for the analysis of large numbers of samples (>500). MASDA utilizes oligonucleotide hybridization to identify DNA sequences. Multiplex DNA samples are immobilized on a solid support and a single hybridization is performed with a pool of allele-specific oligonucleotide (ASO) probes. Any probes that are complementary to specific polymorphisms present in a given sample are effectively affinity purified from the pool by the target DNA. Sequence-specific band patterns (fingerprints) generated by chemical or enzymatic sequencing of the bound ASO(s) readily identify the specific mutation(s).
[0279] There are several alternative hybridization-based technologies, including molecular beacons and Scorpion® probes, among others (Tyagi, S. and Kramer, FR 1996; Thelwell et al., 2000). Molecular beacons are composed of oligonucleotides with fluorescent reporter and quencher dyes at their 5' and 3' ends. The central portion of the oligonucleotide hybridizes across the target sequence, while the 5' and 3' flanking regions are complementary to each other. When not hybridized to their target sequence, the 5' and 3' flanking regions hybridize to form a stem-loop structure and there is little fluorescence due to the proximity of the reporter and quencher dyes. However, after hybridization to their target sequence, the dyes separate and there is a large increase in fluorescence. Mismatched probe-target hybrids dissociate at a substantially lower temperature than exactly complementary hybrids. There are several variants of the "beacon" approach. Scorpion® probes are similar, but incorporate a PCR primer sequence as part of the probe. More recent "duplex" formats have also been developed.
[0280] In some embodiments, additional methods of identifying SNPs include the SNP-IT™ method (Orchid BioSciences, Inc. Princeton, NJ). In general, SNP-IT™ is a three-step primer extension reaction. In the first step, the target polynucleotide is isolated from the sample by hybridization with a capture primer, which provides a first level of specificity. In the second step, the capture primer is extended from the terminating nucleotide triphosphate at the target SNP site, which provides a second level of specificity. In the third step, the extended nucleotide triphosphate can be detected using a variety of known formats, including: direct fluorescence, indirect fluorescence, indirect colorimetric assay, mass spectrometry, fluorescence polarization, etc. The reaction can be processed in a 384-well format in an automated format using an SNPstream™ instrument (Orchid BioSciences, Inc. Princeton, NJ).
[0281] In these embodiments, the amplification products can be detected by Southern blot analysis with or without radioactive probes. In such methods, for example, small samples of DNA containing very low levels of the nucleic acid sequence of the polymorphic locus are amplified and analyzed by Southern blot techniques, or similarly by dot blot analysis. The use of non-radioactive probes or labels is facilitated by the high level of amplified signal. Alternatively, the probes used to detect the amplified products can be detectably labeled, directly or indirectly, for example, with radioisotopes, fluorescent compounds, bioluminescent compounds, chemiluminescent compounds, metal chelators, or enzymes.
[0282] Hybridization conditions, such as salt concentration and temperature, can also be adjusted to screen nucleotide sequences. Southern blot and hybridization protocols are described in Current Protocols in Molecular Biology (Greene Publishing Associates and Wiley-Interscience), pages 2.9.1-2.9.10. Probes can be labeled for hybridization with random oligomers and the Klenow fragment of DNA polymerase. Probes of very high specific activity can be obtained using commercial kits such as Ready-To-Go DNA Labeling Beads (Pharmacia Biotech) following the manufacturer's protocols. Possible competing probes with high repetitive sequence content, as well as the stringency of hybridization and washing, are determined individually for each probe used. Alternatively, fragments of candidate sequences can be generated by PCR and specificity can be verified using rodent-human somatic cell hybrid panels and subcloning the fragments. This allows for large preps for sequencing and use as probes. Once a given gene fragment has been characterized, a small probe preparation can be achieved by gel or column purification of the PCR product.
[0283] Suitable materials that can be used in dot blot, reverse dot blot, multiplex and MASDA formats are well known in the art, and examples include, but are not limited to, nylon and nitrocellulose membranes.
[0284] 3.3 Polymorphic Scanning Technology Scanning techniques contemplated by the present invention for detecting polymorphisms in nucleotide sequences may include, but are not limited to, chemical mismatch cleavage (CMC) (Saleeba, J. A et al., 1992), mismatch repair enzyme cleavage (MREC) (Lu, AL and Hsu, IC, 1992), chemical cleavage techniques, denaturing gradient gel electrophoresis (DGGE) (Wartell et al., 1990; Sheffield et al., 1989), temperature gradient gel electrophoresis (TGGE) (Salimullah, et al. 2005), constant denaturing gel electrophoresis (CDGE), single-strand conformation polymorphism (SSCP) analysis (Kumar, D. et al., 2006), heteroduplex analysis (HA) (Nagamine, CM, et al., 1989), microsatellite marker analysis, and single-strand polymorphism assay (SSPA).
[0285] In some embodiments, the SNPs of the present invention are detected through CMC, where radiolabeled DNA wild-type sequence (i.e., probe) hybridizes to the amplified sequence containing the putative alteration to form a heteroduplex. Chemical modification and subsequent piperidine cleavage are used to remove mismatch bubbles in the heteroduplex. Gel electrophoresis and autoradiography of the denaturing heteroduplex allow visualization of the cleavage products. Osmium tetroxide is used to modify mismatched thymidines and hydroxylamines for mismatched cytosines. Furthermore, labeling of the antisense strand of the probe DNA allows detection of adenosine and guanosine mismatches. Chemical cleavage of mismatches can be used to detect nearly 100% of mutations in long DNA fragments. Furthermore, this method provides precise characterization and precise location of mutations in the test fragments. Recently, this method has been improved to make CMC more suitable for automation by using fluorescent primers, which also allow multiplexing, thereby reducing the number of operations. Alternatively, fluorescently labeled dUTP incorporated by PCR allows for internal labeling of both the target and probe DNA strands and thus of each possible hybrid, doubling the chances of mutation detection and virtually guaranteeing 100% detection.
[0286] In other embodiments, a mismatch repair enzyme cleavage (MREC) assay is used to identify the SNPs of the present invention. MREC relies on a nicking enzyme system that is specific for mismatch-containing DNA. The sequence of interest is amplified by PCR, and homo- and heteroduplex species can be generated at the ends of the PCR by denaturing and reannealing the amplified products. These hybrids are treated with mismatch repair enzymes and then analyzed by denaturing gel electrophoresis. The MREC assay utilizes three mismatch repair enzymes. MutY endonuclease removes adenines from mismatches, which is useful for detecting both A / T and C / G transversions and G / C and T / A transversions. Mammalian thymine glycosylase removes thymines from T / G, T / C and T / T mismatches, which is useful for detecting G / C and A / T transversions and A / T and G / C and T / A and A / T transversions. All types of endonucleases or topoisomerase I from human or calf thymus can recognize all eight mismatches and can be used to check for any nucleotide substitution. MREC can use specific labels that can be incorporated into both DNA strands, thus allowing the identification of all four possible nucleotide substitutions at a given site.
[0287] In some embodiments, chemical cleavage analysis, as described in US Patent No. 5,217,863, is used to identify SNPs in nucleotide sequences.Similar to heteroduplex analysis, chemical cleavage detects the different properties that mismatched allele sequences bring about when hybridized with each other.Instead of detecting this difference as the change in migration speed on gel, this difference is detected in the change in the susceptibility of hybrids to chemical cleavage, for example, using hydroxylamine or osmium tetroxide, followed by piperidine.
[0288] In the cleavage method contemplated by the present invention, RNase A relies on the principle of heteroduplex mismatch analysis. In the RNase cleavage method, the RNA-DNA heteroduplex between radiolabeled riboprobe and DNA obtained by PCR amplification is enzymatically cleaved by RNase A by utilizing the ability of RNase A to cleave single-stranded RNA at the mismatched position in RNA:DNA hybrid. This is followed by electrophoresis and autoradiography. The presence and position of mutations are indicated by the cleavage products of a given size (Meyers, RM, et al., 1985; Gibbs, RA and Caskey, T., 1987).
[0289] DNA probes can also be used to detect mismatches through enzymatic or chemical cleavage; see Cotton, et al., 1988; Shenk et al., 1975 and Novack et al., 1986.
[0290] In some embodiments, the Invader® assay (Third Wave™ technology) can be used to examine polymorphisms in the 16S rRNA gene of the present invention. For example, the Invader® assay is based on the recognition of the three-dimensional structure formed when two overlapping oligonucleotides perfectly hybridize to the target DNA, and the specificity of cleavage by the Flap endonuclease (Lyamichev, V. et al., 1999).
[0291] Alternatively, denaturing gradient gel electrophoresis (DGGE) is a useful technique to separate and identify sequence variants. DGGE is commonly performed in constant concentration polyacrylamide gel slabs, cast in the presence of linearly increasing amounts of denaturant (usually formamide and urea, cathode to anode). A variant of DGGE uses a temperature gradient along the migration path and is known as TGGE. Separation by DGGE or TGGE is based on the fact that the electrophoretic mobility in the gel of partially melted DNA molecules is greatly reduced compared to unmelted molecules.
[0292] In some embodiments, constant denaturing gel electrophoresis (CDGE), as described in detail in Smith-Sorenson et al., 1993, is useful for detecting SNPs in nucleotide sequences. A given DNA duplex melts in a gel of constant denaturant in a predefined characteristic way. Mutations alter this behavior. To determine the specific mutation, the aberrant migrating fragments are isolated and sequenced.
[0293] In another embodiment, single-strand conformation polymorphism (SSCP) analysis provides a method for detecting the SNPs of the present invention. SSCP is a method based on the change in mobility of separated single-stranded DNA molecules in non-denaturing polyacrylamide gel electrophoresis. Electrophoretic mobility depends on both the size and shape of the molecule, and single-stranded DNA molecules fold themselves to generate secondary structures, which are determined by intramolecular interactions in a sequence-dependent manner. Single nucleotide substitutions can alter the secondary structure and, as a consequence, the electrophoretic mobility of the single strand, resulting in a band shift on the autoradiograph. The ability of a given nucleotide mutation to alter the conformation of a single strand is not predictable based on sufficient theoretical models, and base changes occurring in loops or in long stable stems of secondary structures may not be detectable by SSCP. Standard SSCP reaches maximum confidence in the detection of sequence changes in fragments of 150-200 bp. More advanced protocols have been developed that allow the detection of mutations with a sensitivity equal to that of radioactivity-based SSCP analysis. These methods use fluorescently labeled primers in PCR and analyze the products with fluorescence-based automated sequencing instruments. Multicolor fluorescent SSCP also allows for the inclusion of an internal standard in every lane, which can be used to compare data from each lane against each other. Other variants that increase the detection rate include dideoxy sequencing approaches based on dideoxy fingerprinting (ddF) and restriction endonuclease fingerprinting (REF).
[0294] The ddF method is a combination of SSCP and Sanger dideoxy sequencing, which involves non-denaturing gel electrophoresis of the Sanger sequencing reaction with one dideoxynucleotide. With this method, for example, fragments of 250 bp can be screened to identify SNPs. REF is a more complex modification of SSCP, which allows screening of fragments larger than 1 kb. For REF, the target sequence is amplified by PCR, digested independently with 5-6 different restriction endonucleases, and analyzed by SSCP on a non-denaturing gel. If six restriction enzymes are used, the sequence mutation will be present in six different restriction fragments, thus generating 12 different single-stranded segments. A mobility shift in any one of these fragments is sufficient to pinpoint the presence of a SNP of the invention. The resulting restriction pattern allows localization of the alteration in the interrogation region.
[0295] In some embodiments, heteroduplex analysis (HA) detects single base substitutions in PCR products or nucleotide sequences. HA can be performed quickly without radioisotopes or specialized equipment. HA methods utilize the formation of heteroduplexes between sequences with different nucleotides at one or more positions by heating and denaturing PCR products. Due to the more open duplex configuration surrounding the mismatched base, heteroduplexes migrate slower than their corresponding homoduplexes and are subsequently detected as bands of reduced mobility. The ability of a particular single base substitution to be detected by the HA method cannot be predicted by knowing the mismatched base alone, because adjacent nucleotides have a substantial effect on the configuration of the mismatched region, and length-based separation would obviously miss the nucleotide substitution. Optimization of temperature, gel crosslinking and concentration of acrylamide, as well as glycerol and sucrose used enhances the resolution of mutated samples. HA methods can be performed quickly without radioisotopes or specialized equipment to screen a large number of samples for known mutations and polymorphisms in sequenced genes. When HA is used in conjunction with SSCP, up to 100% of all alterations within a DNA fragment can be easily detected.
[0296] In some embodiments, the use of proteins that recognize nucleotide mismatches, such as the mutS protein of E. coli, can be used to detect polymorphisms in the 16S rRNA of the present invention (Modrich 1991). In the mutS assay, the protein binds only to sequences that contain a nucleotide mismatch in the heteroduplex between the two sequences.
[0297] In a further embodiment, polymorphism detection can be performed using microsatellite marker analysis. For example, microsatellite markers with an average genomic spacing of about 10 centimorgans (cM) can be used using standard DNA isolation methods known in the art.
[0298] The SSPA assay described above and the closely related heteroduplex analysis method can be used to screen for single nucleotide polymorphisms (Orita, M. et al., 1989).
[0299] 3.4 Nucleotide arrays and gene chips for polymorphism analysis The present invention further contemplates a method for identifying SNPs through the use of an array of oligonucleotides, such as at least 12nt, at least about 15nt, at least about 18nt, at least about 20nt or at least about 25nt, or longer, that comprise sequences adjacent to polymorphic positions, where distinct positions on the array are complementary to one or more of the sequences that contain the SNPs of the present invention.Such arrays can comprise consecutive oligonucleotides, each of which can specifically hybridize to a different polymorphism.For examples of arrays, see Hacia et al., 1996 and De Risi et al., 1996.
[0300] Nucleotide arrays can include all or a subset of the polymorphisms of the invention, as desired. One or more polymorphic forms may be present on the array. The oligonucleotide sequences on the array are generally at least about 12 nt, at least about 15 nt, at least about 18 nt, at least about 20 nt, or at least about 25 nt in length, or longer, e.g., 100-200 nt in length. For examples of arrays, see Ramsay 1998; Hacia et al., 1996; Lockhart et al., 1996, and De Risi et al., 1996.
[0301] Several methods are available for making microarrays of biological samples, such as the arrays of DNA samples used in DNA hybridization assays.Examples of such arrays are discussed in detail in PCT Application WO 95 / 35505; U.S. Patent Application No. 5,445,934; and Drmanac et al., 1993.Yershov et al., 1996, describes alternative construction of oligonucleotide arrays.Construction and use of oligonucleotide arrays are reviewed by Ramsay (1998).
[0302] The method of using high-density oligonucleotide arrays to identify polymorphisms in nucleotide sequences is known in the art.For example, Milosavljevic et al., 1996 describes DNA sequence recognition by hybridization to short oligomers (see also Drmanac et al., 1998 and Drmanac and Drmanac, 1999).The use of arrays for identifying unknown mutations is proposed by Ginot 1997.
[0303] Detection of known mutations is described in Hacia et al. 1996; Cronin et al., 1996; and others. The use of arrays in gene mapping is discussed in Chee et al., 1996; Sapolsky and Lishutz, 1996, and Shoemaker et al., 1996.
[0304] Quantitative monitoring of gene expression patterns by complementary DNA microarrays is described in Schena et al., 1995 and DeRisi et al., 1997. Wodicka et al., 1997 perform genome-wide expression monitoring in S. cerevisiae.
[0305] High density microarrays of oligonucleotides are known in the art and are commercially available. The oligonucleotide sequences on the array correspond to known target sequences. The length of the oligonucleotides present on the array is an important factor of how sensitive hybridization is to the presence of mismatches. Usually, oligonucleotides are at least about 12nt long, more usually at least about 15nt long, preferably at least about 20nt long, more preferably at least about 25nt long, and are not longer than about 35nt long, and are usually less than about 30nt long.
[0306] Methods for producing large arrays of oligonucleotides are described in US Patent No. 5,134,854 and US Patent No. 5,445,934 using light-induced synthesis technology.By using a computer-controlled system, a heterogeneous array of monomers is converted into a heterogeneous array of polymers through simultaneous coupling at several reaction sites.Alternatively, microarrays are produced by deposition of presynthesized oligonucleotides onto solid substrates, as described, for example, in WO 95 / 35505.
[0307] The microarray can be interrogated to detect the hybridization of the labeled genomic sample. Methods and devices for detecting fluorescently marked targets with an apparatus are known in the art. Generally, such detection devices include a microscope and a light source for directing light to the substrate. A photon counter detects the fluorescence from the substrate while an xy translation stage changes the position of the substrate. A confocal detection device that can be used in the subject method is described in U.S. Pat. No. 5,631,734. A scanning laser microscope is described in Shalon et al. 1996. A scan with an appropriate excitation system is performed for each fluorophore used. The digital images generated from the scans are then merged for further analysis. For any particular array element, the ratio of the fluorescent signal from one nucleic acid sample is compared to the fluorescent signal from the other nucleic acid sample to determine the relative signal strength.
[0308] Methods for analyzing data collected by fluorescence detection are known in the art. Data analysis includes determining the fluorescence intensity corresponding to the substrate position from the collected data, removing outliers, i.e., data that deviates from a predetermined statistical distribution, and calculating the relative binding affinity of the target from the remaining data. The resulting data can be presented as an image, with the intensity of each region varying according to the binding affinity between the target and the probe.
[0309] Nucleic acid analysis through microchip technology is also applicable to the present invention. In this technology, thousands of separate oligonucleotide probes can be applied to an array on a silicon chip. The nucleic acids to be analyzed are fluorescently labeled and hybridized to the probes on the chip. These nucleic acid microchips can also be used to study nucleic acid-protein interactions. This technology can be used to determine the presence of mutations, to sequence the nucleic acids to be analyzed, or to measure the expression level of genes of interest. The method is one of parallel processing of many, even thousands, of probes at once, which can greatly increase the speed of analysis.
[0310] Alterations in mRNA transcription can be detected by any technique known to those of skill in the art. These include Northern blot analysis, PCR amplification and RNase protection. Reduced mRNA transcription indicates an alteration in the sequence.
[0311] Array / chip technology has already been successfully applied in many cases.
[0312] For example, mutation screening has been performed in the BRCA1 gene, mutant strains of S. cerevisiae, and the protease gene of the HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996; Kozal et al., 1996). Chips of various formats for use in the detection of SNPs can be produced by customization.
[0313] Array-based tiling strategies that are useful for the detection of SNPs are described in EP 785280. Briefly, arrays can be generally "tiled" for a number of specific polymorphisms. "Tiling" refers to the synthesis of a defined set of oligonucleotide probes that are composed of a sequence that is complementary to a target sequence of interest, as well as preselected mutations of that sequence, e.g., substitutions of one or more given positions with one or more members of a base set of monomers, i.e., nucleotides. Tiling strategies are further described in PCT Application WO 95 / 11995. In some embodiments, arrays are "tiled" for several specific SNPs. In detail, arrays are tiled to include several detection blocks, each detection block specific to a specific SNP or set of SNPs. For example, detection blocks can be tiled to include several probes that span a sequence segment that includes a specific SNP. To ensure that probes are complementary to each allele, probes are synthesized in sets that differ in SNP position. In addition to probes that differ in SNP position, single-substitution probes are also generally tiled within a detection block. Such methods can be readily applied to the SNP information disclosed herein.
[0314] These single-substitution probes have a certain number of bases in either direction from the polymorphism substituted with the remaining nucleotides (selected from A, T, G, C, and U). Typically, the probes in the tiled detection block contain substitutions at sequence positions up to and including 5 bases away from the SNP. The single-substitution probes provide an internal control for the tiled array to distinguish real hybridization from artificial cross-hybridization. After hybridization with the target sequence and washing of the array, the array is interrogated to determine the position of the array to which the target sequence hybridizes. Hybridization data from the interrogated array is then analyzed to determine which allele or alleles of the SNP are present in the sample. Hybridization and scanning can be performed as described in PCT Publications WO 92 / 10092 and WO 95 / 11995 and U.S. Pat. No. 5,424,186.
[0315] Thus, in some embodiments, the chip can comprise an array of nucleic acid sequences of fragments of about 15 nucleotides in length and sequences complementary thereto or fragments thereof, the fragments comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47 or 50 consecutive nucleotides, and containing a polymorphic base. In some embodiments, the polymorphic base is within 5, 4, 3, 2 or 1 nucleotides from the center of the polynucleotide, more preferably at the center of the polynucleotide. In other embodiments, the chip can comprise an array containing any number of polynucleotides of the present invention.
[0316] Oligonucleotides can be synthesized on the surface of a substrate using chemical coupling procedures and inkjet coating equipment, as described in PCT Application WO 95 / 251116. In another embodiment, a "grid" array similar to a dot (or slot) blot can be used to place and link cDNA fragments or oligonucleotides on the surface of a substrate using vacuum systems, heat, UV, mechanical or chemical bonding procedures. Arrays such as those above can be generated manually or using available equipment (slot blot or dot blot equipment), materials (any suitable solid support) and machines (including robotic equipment), and can contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number that is conducive to the efficient use of commercially available equipment.
[0317] Using such an array, the present invention provides a method for identifying the SNPs of the present invention in a sample. Such a method includes incubating a test sample with an array containing one or more oligonucleotide probes corresponding to at least one SNP position of the present invention, and examining nucleic acid from the test sample for binding to one or more of the oligonucleotide probes. Such an assay typically involves an array containing oligonucleotide probes corresponding to many SNP positions and / or allelic variants of those SNP positions, at least one of which is a SNP of the present invention.
[0318] The conditions for incubating nucleic acid molecules with test samples vary. Incubation conditions depend on the format used in the assay, the detection method used, and the type and nature of the nucleic acid molecules used in the assay. Those skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can easily be adapted to use the novel SNPs disclosed herein. Examples of such assays can be found in Chard, T, An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, GR et al., Techniques in Immunocytochemistry, Academic Press, Orlando, Fla. Vol. 1 (I 982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).
[0319] Multi-component integrated systems can also be used to analyze SNPs. Such systems miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions into a single functional device. An example of such technology is disclosed in US Patent No. 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in a chip.
[0320] Integrated systems can be envisaged when primarily microfluidic mechanical systems are used. These systems include a pattern of microchannels designed onto a glass, silicon, quartz or plastic wafer contained on a microchip. Sample movement is controlled by electrical, electroosmotic or hydrostatic forces applied across different regions of the microchip to create functional microscopic valves and pumps without moving parts. Fluid flow rates are controlled at the intersections between the microfabricated channels by varying the voltage, varying the fluid flow rate to pump across different parts of the microchip.
[0321] For SNP genotyping, microfluidic systems can integrate detection methods such as, for example, nucleic acid amplification, minisequencing primer extension, capillary electrophoresis and laser-induced fluorescence detection.
[0322] In the first step, the DNA sample is amplified, preferably by PCR. The amplified products are then subjected to an automated mini-sequencing reaction using ddNTPs (specific fluorescence for each ddNTP) and appropriate oligonucleotide mini-sequencing primers that hybridize immediately upstream of the targeted polymorphic base. Once the 3'-end extension is complete, the primers are separated from the unincorporated fluorescent ddNTPs by capillary electrophoresis. The separation medium used in capillary electrophoresis can be, for example, polyacrylamide, polyethylene glycol or dextran. The ddNTPs incorporated into the single nucleotide primer extension products are identified by laser-induced fluorescence detection. The microchip can be used to process at least 96-384 samples or more in parallel.
[0323] 3.5 Extension-Based Techniques for Polymorphism Detection Extension-based techniques for detecting polymorphisms in nucleotide sequences can include, but are not limited to, allele-specific amplification, also known as the amplification resistant mutation system (ARMS), disclosed in European Patent Application Publication No. 0332435 and Newton et al., 1989, and cloning of polymorphisms contemplated (COPS) by Gibbs et al., 1989.
[0324] Extension-based techniques (ARMS) use allele-specific oligonucleotide (ASO) PCR primers for genotyping. In this approach, one of the two oligonucleotide primers used for PCR is designed to bind to the polymorphic site, most commonly the 3' end of the primer targeting that site. Under carefully controlled conditions (annealing temperature, magnesium concentration, etc.), amplification will occur only if the nucleotide at the 3' end of the PCR primer is complementary to the base at the polymorphic site, making the mismatch "resistant" to amplification.
[0325] A variant of the ARMS approach, termed mutagenesis-induced separation PCR (MS-PCR), involves two ARMS primers of different lengths, each specific for a different polymorphism at a site. This method gives PCR products of different lengths for different polymorphisms.
[0326] 3.6 Ligation-Based Assays for Detecting Polymorphisms Another common method of SNP detection involves oligonucleotide ligation assays. Some approaches utilize DNA ligase, an enzyme that can join two adjacent oligonucleotides hybridized to a DNA template. The specificity of this approach comes from the requirement of a perfect match between the hybridized oligonucleotide and the DNA template at the ligation site. In an oligonucleotide ligation assay (OLA) or ligase chain reaction (LCR) assay, the sequence surrounding the mutation site is first amplified, and one strand serves as a template for three ligation probes, two of which are allele-specific oligonucleotides (ASOs) and the third is a common probe. For detection of the ligation products, a number of approaches can be used. For example, the two ASOs can be differentially labeled with fluorescent or hapten labels, and the ligation products can be detected by fluorescent or colorimetric enzyme-linked immunosorbent assays, respectively. For electrophoresis-based systems, the use of mobility modifier tags or probe length variations together with fluorescent detection allows multiplex genotyping of several single nucleotide substitutions in a single tube. When used on an array, the ASO can be found at a specific location or address on the chip. PCR amplified DNA can then be added and ligation to the labeled oligonucleotide at the specific address on the array can be measured.
[0327] 3.7 Signal-Generating Polymorphism Detection Assays In some embodiments, fluorescence resonance energy transfer (FRET) is considered a method to identify polymorphisms in the 16S rRNA gene. FRET occurs due to the interaction between the electronic excited states of two dye molecules. Excitation is transferred from one (donor) dye molecule to the other (acceptor) dye molecule without the emission of a photon. It is distance dependent, i.e. the donor and acceptor dyes must be in close proximity. The hybridization probe system consists of two oligonucleotides labeled with fluorescent dyes. The hybridization probe pair is designed to hybridize to adjacent regions on the target DNA. Each probe is labeled with a different marker dye. The interaction of the two dyes can only occur when both are bound to their targets. The donor probe is labeled with a fluorophore at the 3' end and the acceptor probe is labeled with a fluorophore at the 5' end. During PCR, the two different oligonucleotides hybridize to adjacent regions of the target DNA, so that the fluorophores attached to the oligonucleotides are in close proximity to the hybrid structure. A donor fluorophore (F1) is excited by an external light source and then passes a portion of its excitation energy to an adjacent acceptor fluorophore (F2), which emits light at a different wavelength, which can then be detected and measured for molecular proximity.
[0328] In another embodiment, the MagSNiPer method based on single base extension, magnetic separation and chemiluminescence provides a further method for SNP identification in nucleotide sequences. A single base nucleotide extension reaction is carried out with a biotinylated primer whose 3' end is continuous with the SNP site with tagged ddNTP. The primer is then captured by magnetic coating beads with streptavidin, and unincorporated labeled ddNTP is removed by magnetic separation. The magnetic beads are incubated with an anti-tag antibody conjugated to alkaline phosphatase. After removing excess conjugate by magnetic separation, SNP typing is carried out by measuring chemiluminescence. The incorporation of labeled ddNTP is monitored by chemiluminescence induced by alkaline phosphatase.
[0329] In some embodiments, the fluorescence polarization method provides a method for identifying polymorphisms in nucleotide sequences. For example, amplified DNA containing polymorphisms is incubated with oligonucleotide primers (designed to hybridize to the DNA template adjacent to the polymorphic site) in the presence of allele-specific dye-labeled dideoxyribonucleoside triphosphates and commercially available modified Taq DNA polymerase. The primers are extended by dye-terminators that are specific to the alleles present on the template, increasing the molecular weight of the fluorophore by approximately 10-fold. At the end of the reaction, the fluorescence polarization of the two dye-terminators in the reaction mixture is directly analyzed without separation or purification. This homogeneous DNA diagnostic method has been shown to be highly sensitive and specific, and is suitable for automated genotyping of a large number of samples.
[0330] In another embodiment, surface-enhanced Raman scattering can be used as a method to detect and identify single base differences in double-stranded DNA fragments (see Chumanov, G 1999). SERS has also been used for single molecule detection (Kneipp, K, 1997). SERS results in a greatly increased Raman signal from molecules attached to nanometer-sized metal structures.
[0331] Illustrative examples include the genotyping method discussed by Xiao and Kwok 2003, where detection is based on a primer extension assay with fluorescence quenching. The template-directed dye-terminator incorporation with fluorescence quenching detection (FQ-TDI) assay is based on the observation that the intensity of fluorescent dyes R110- and R6G-labeled acycloterminators is universally quenched when they are incorporated into DNA oligonucleotide primers. By comparing the kinetics of fluorescence quenching of the two allelic dyes in real time, the frequency of SNPs in DNA samples can be measured. The dynamic FQ-TDI assay is highly accurate and reproducible for both genotyping and allele frequency estimation.
[0332] 3.8 High-resolution melting analysis In certain embodiments, the methods of the present invention utilize high resolution melting (HRM) analysis to classify and / or identify one or more bacteria in a sample based on the SNP(s) described herein in the 16S rRNA gene, in the 16S rRNA molecule, or in the DNA copy thereof.
[0333] HRM is a method to measure the melting temperature (T m In contrast to traditional melting, the information in HRM analysis is based on the precise monitoring of the change in fluorescence as the protein is heated through a calculated T m Since the data are not only collected but also in the form of a melting curve, HRM can be considered a form of spectroscopy. HRM analysis is a single-step, closed-tube method, and amplification and melting can be performed as a single protocol on a real-time PCR instrument.
[0334] In an embodiment of the invention, the method utilizes an amplification primer pair that selectively hybridizes to a target polynucleotide containing one or more of the SNPs described herein. The amplification reaction mixture contains a fluorescent dye, which is incorporated into the resulting amplicon.
[0335] The resulting amplicon is then subjected to HRM at incremental increases in temperature (i.e., 0.01-0.5° C.) within the range of about 50° C. to about 95° C. At some point during this process, the melting temperature of the amplicon is reached and the two strands of DNA separate or "melt" apart.
[0336] HRM is monitored in real time using a fluorescent dye that is incorporated into the amplicon. The fluorescence level of the dye is monitored as the temperature is increased, and fluorescence decreases as the amount of double-stranded DNA decreases. The changes in fluorescence and temperature can be plotted on a graph known as a melting curve.
[0337] As one of skill in the art will appreciate, the T of an amplicon at which the two DNA strands separate m is predictable and depends on the sequence of nucleotide bases that form the amplicon.Thus, the melting curves appear differently, and it is possible to distinguish amplicons that contain polymorphisms (i.e., one or more SNPs).In fact, in some embodiments, it is possible to distinguish amplicons that contain the same polymorphism based on the difference in the surrounding DNA sequence.
[0338] HRM curves can be distinguished from one another by many different strategies. For example, in many cases, HRM curves can be distinguished based on obvious differences in curve shape and / or based on Tm, with differences of 0.2°C being considered significant. In other cases, difference graph analysis can be used, where a given curve is used as a baseline and other normalized curves are plotted against the baseline (see Price, EP et al. 2007). In still other cases, a difference graph-based method can be used, which involves deriving the 3rd and 97th percentile values from the mean ± 1.96 standard deviation for fluorescence at all temperatures (see Andersson, P. et al., 2009 and Merchant-Patel, S. et al. 2008).
[0339] 4. Tools, Reagents, Primers, Probes, Kits and Processing Systems This specification describes how various SNPs can be used as "tools" for identifying, partially identifying or classifying bacteria, yeast organisms or filamentous fungi, or for diagnosing infections by bacteria, yeast organisms or filamentous fungi. Knowledge of the SNPs allows inventors to develop gene / allele-based and gene product-based probes, tools, reagents, methods and assays for identifying, partially identifying or classifying bacteria, yeast organisms or filamentous fungi, or for diagnosing infections by bacteria, yeast organisms or filamentous fungi.
[0340] Based on the information provided herein, particularly in Tables 1-9 and 11, one of skill in the art can readily design, generate or manufacture a wide range of gene / allele-based and gene product-based probes, tools, reagents, methods and assays.
[0341] Generally, such probes, tools or reagents based on or developed with the SNPs outlined herein in mind can, for example, specifically bind to, detect, identify, characterize or quantitate a gene or a portion of a gene, an RNA gene product or a portion of an RNA gene product, or other gene product or portion thereof.
[0342] In general, such probes, tools or reagents may be for the detection of polymorphisms, for example, at the genomic or transcriptional level.
[0343] Generally, such a probe, tool or reagent may be an antibody or other type of molecule or chemical entity capable of detecting a gene or a gene product (such as RNA).
[0344] More specifically, the probes, tools and reagents may include, but are not limited to: 1. Isolated, purified, synthetic or recombinant forms of 16S rRNA, 16S rDNA, 18S rRNA or 18S rDNA, or fragments thereof - single or double stranded, including fragments containing a SNP of interest. 2. A non-naturally occurring polynucleotide, recombinant polynucleotide, oligonucleotide or cDNA form of 16S rRNA, 16S rDNA, 18S rRNA or 18S rDNA, or a fragment thereof - single or double stranded, including a fragment containing a SNP of interest. 3. An expression vector, recombinant cell or biological sample comprising a nucleic acid or polynucleotide of 1 or 2.
[0345] A probe, tool or reagent may be, without limitation, an antibody or other type of molecule or chemical entity capable of detecting a gene or a gene product (RNA or polypeptide).
[0346] The at least one probe, tool or reagent may be any number or combination of the above, the number and combination depending on the desired result to be achieved - e.g., detection of polymorphisms at the genome level (genotyping), RNA level.
[0347] All essential materials and reagents required for detecting one or more SNPs in the 16S rRNA gene or 18S rRNA gene according to the present invention can be packaged together in a kit. The kit may include suitable labeled detection reagents, positive and negative controls, fluorescent dyes, washing solutions, blotting membranes, microtiter plates, dilution buffers, etc. For example, a nucleic acid-based detection kit for the identification of polymorphisms may include one or more of the following: (i) nucleic acid from Gram-positive and / or Gram-negative cells (which can be used as a positive control); and (ii) primers and / or probes that specifically hybridize to at least a portion of the 16S rRNA gene or 18S rRNA gene containing the SNP position(s) to be analyzed, and optionally one or more other markers at or around the suspected SNP site. Enzymes suitable for nucleic acid amplification, including various polymerases (reverse transcriptase, Taq, Sequenase™ DNA ligase, etc., depending on the nucleic acid amplification technique used), deoxynucleotides and buffers may be included to provide the necessary reaction mixture for amplification. Such kits will also typically include, in suitable means, separate containers for each individual reagent and enzyme, and each primer or probe. The kits may also feature various equipment and reagents for carrying out one of the assays described herein; and / or printed instructions for using the kit to identify the presence of a SNP as defined herein.
[0348] In some embodiments, the methods generally described herein are performed at least in part by a processing system, such as a suitably programmed computer system. A stand-alone computer with a microprocessor running application software that allows the execution of the above-mentioned methods can be used. Alternatively, the methods can be performed at least in part by one or more processing systems operating as part of a distributed architecture. For example, the processing system can be used to detect the presence of a SNP at a location by detecting hybridization of a probe to a nucleic acid molecule. The processing system can also be used to determine the gram state or identity or grouping of bacteria based on the detection of one or more SNPs. In some examples, commands entered into the processing system by a user can assist the processing system in these determinations.
[0349] In one example, the processing system includes at least one microprocessor, a memory, an input / output device, such as a keyboard and / or a display device, and an external interface interconnected through a bus. The external interface can be utilized to connect the processing system to peripheral devices, such as a communication network, a database, or a storage device. The microprocessor can execute instructions in the form of application software stored in the memory to enable the execution of SNP detection and / or microbial identification or classification processes, as well as to perform any other required processes, such as communication with a computer system. The application software can include one or more software modules and can be executed in a suitable execution environment, such as an operating system environment.
[0350] 4.1 Primers, probes, kits and processing systems for 16S rRNA genes or 18S rRNA genes The present invention provides probes and primers that can be used in the methods described herein to determine SNPs at one or more positions in the 16S or 18S rRNA gene to classify and / or identify one or more bacteria, yeast organisms or filamentous fungi in a sample.
[0351] The primers and probes of the present invention hybridize to at least a portion of the 16S rRNA gene or 18S rRNA gene (or a 16S rRNA molecule or a DNA copy thereof or an 18S rRNA molecule or a DNA copy thereof) that contains the SNP position(s). For example, the primers can hybridize to sequences adjacent to one or more SNPs, and the probes can hybridize to sequences that include one or more SNPs. It is within the skill of the art to design suitable primers and probes for use in the methods of the present invention based on the known sequence of the 16S rRNA gene or 18S rRNA gene.
[0352] Non-limiting examples of primers and probes useful for the methods of the invention in which SNPs at positions in the 16S rRNA of a bacterial species corresponding to positions 273, 378, 412, 440, 488, 647 and / or 653 of the 16S rRNA gene set forth in SEQ ID NO:1 are analyzed include those described in Example 1.
[0353] For example, to detect the SNP at position 273, an exemplary forward primer includes: Exemplary reverse primers include CCTCTTGCCATCGGATGTG (SEQ ID NO: 16), and exemplary reverse primers include CCAGTGTGGCTGGTCATCCT (SEQ ID NO: 17), CGATCCGAAAACCTTCTTCACT (SEQ ID NO: 20), CTATGCATCGTTGCCTTGGTAA (SEQ ID NO: 22), TGATGTACTATTAACACATCAACCTTCCT (SEQ ID NO: 26), AACGCTCGGATCTCCGTATTA (SEQ ID NO: 27), CGCTCGCCACCTACGTATTAC (SEQ ID NO: 28), CGTAGTTAGCCGTCCCTTTCTG (SEQ ID NO: 30), GGAATTCTCACCCCCCTCTACGA (SEQ ID NO: 34), and GGAATTCTACCCCCCTCTACAAG (SEQ ID NO: 35).
[0354] To detect the SNP at position 378, exemplary forward primers include CCTCTTGCCATCGGATGTG (SEQ ID NO: 16), CCTACGGGAGGCAGCAGTAG (SEQ ID NO: 18), and GGGAGGCAGCAGTAGGGAAT (SEQ ID NO: 19); and exemplary reverse primers include CGATCCGAAAACCTTCTTCACT (SEQ ID NO: 20), CTATGCATCGTTGCCTTGGTAA (SEQ ID NO: 22), TGATGTACTATTAACACATCAACCTTCCT (SEQ ID NO: 26), AACGCTCGGATCCGTATTA (SEQ ID NO: 27), CGCTCGCCACCTACGTATTAC (SEQ ID NO: 28), CGTAGTTAGCCGTCCCTTTCTG (SEQ ID NO: 30), GGAATTCTACCCCCTCTACGA (SEQ ID NO: 34), and GGAATTCTACCCCCCTCTACAAG (SEQ ID NO: 35).
[0355] To detect the SNP at position 412, exemplary forward primers include CCTCTTGCCATCGGATGTG (SEQ ID NO: 16), CCTACGGGAGGCAGCAGTAG (SEQ ID NO: 18), GGGAGGCAGCAGTAGGGAAT (SEQ ID NO: 19), and AAGACGGTCTTGCTGTCACTTATAGA (SEQ ID NO: 21); and exemplary reverse primers include CTATGCATCGTTGCCTTGGTAA (SEQ ID NO: 22), TGATGTACTATTAACACATCAACCTTCCT (SEQ ID NO: 26), AACGCTCGGATCCGTATTA (SEQ ID NO: 27), CGCTCGCCACCTACGTATTAC (SEQ ID NO: 28), CGTAGTTAGCCGTCCCTTTCTG (SEQ ID NO: 30), GGAATTCTACCCCTCTACGA (SEQ ID NO: 34), and GGAATTCTACCCCCCTCTACAAG (SEQ ID NO: 35).
[0356] To detect the SNP at position 440, exemplary forward primers include CCTCTTGCCATCGGATGTG (SEQ ID NO: 16), CCTACGGGAGGCAGCAGTAG (SEQ ID NO: 18), GGGAGGCAGCAGTAGGGAAT (SEQ ID NO: 19), AAGACGGTCTGCTGTCACTTATAGA (SEQ ID NO: 21), TGCCGCGTGAATGAAGAA (SEQ ID NO: 23), GCGTGAAGGATGAAGGCTCTA (SEQ ID NO: 24), and TGATGAAGGTTTTCGGATCGT (SEQ ID NO: 25); and exemplary reverse primers include TGATGTACTATTAACACATCAACCTTCCT (SEQ ID NO: 26), AACGCTCGGATCCGTATTA (SEQ ID NO: 27), CGCTCGCCACCTACGTATTAC (SEQ ID NO: 28), CGTAGTTAGCCGTCCCTTTCTG (SEQ ID NO: 30), GGAATTCTACCCCTCTACGA (SEQ ID NO: 34), and GGAATTCTACCCCCCTCTACAAG (SEQ ID NO: 35).
[0357] To detect the SNP at position 488, exemplary forward primers include CCTCTTGCCATCGGATGTG (SEQ ID NO: 16), CCTACGGGAGGCAGCAGTAG (SEQ ID NO: 18), GGGAGGCAGCAGTAGGGAAT (SEQ ID NO: 19), AAGACGGTCTGCTGTCACTTATAGA (SEQ ID NO: 21), TGCCGCGTGAATGAAGAA (SEQ ID NO: 23), GCGTGAAGGATGAAGGCTCTA (SEQ ID NO: 24), TGATGAAGGTTTTCGGATCGT (SEQ ID NO: 25), and GTTGTAAGAGAAGAACGAGTGTGAGAGT (SEQ ID NO: 29); and exemplary reverse primers include CGTAGTTAGCCGTCCCTTTCTG (SEQ ID NO: 30), GGAATTCTACCCCCCTCTACGA (SEQ ID NO: 34), and GGAATTCTACCCCCCTCTACAAG (SEQ ID NO: 35).
[0358] To detect the SNPs at positions 647 and / or 653, exemplary forward primers include CCTCTTGCCATCGGATGTG (SEQ ID NO: 16), CCTACGGGAGGCAGCAGTAG (SEQ ID NO: 18), GGGAGGCAGCAGTAGGGAAT (SEQ ID NO: 19), AAGACGGTCTGCTGTCACTTATAGA (SEQ ID NO: 21), TGCCGCGTGAATGAAGAA (SEQ ID NO: 23), GCGTGAGGATGAAGGCTCTA (SEQ ID NO: 24), TGATGAAGGTTTTCGG Exemplary reverse primers include ATCGT (SEQ ID NO: 25), GTTGTAAGAGAAGAACGAGTGTGAGAGT (SEQ ID NO: 29), GCGGTTTGTTAAGTCAGATGTGAA (SEQ ID NO: 31), GGTCTGTCAAGTCGGATGTGAA (SEQ ID NO: 32), and TCAACCTGGGAACTCATTCGA (SEQ ID NO: 33); and exemplary reverse primers include GGAATTCTACCCCCCTCTACGA (SEQ ID NO: 34), and GGAATTCTACCCCCCTCTACAAG (SEQ ID NO: 35).
[0359] Similarly, non-limiting examples of primers and probes useful for the methods of the invention in which SNPs at positions in the 16S rRNA gene or 16S rRNA of a bacterial species corresponding to positions 746, 764, 771 or 785 of the 16S rRNA gene set forth in SEQ ID NO:43 (or positions 737, 755, 762 or 776 of the 16S rRNA gene set forth in SEQ ID NO:1) are analyzed include those set forth in Table 8.
[0360] Similarly, non-limiting examples of primers and probes useful for the methods of the invention in which SNPs at positions 343, 371, 388, 416 and 467 of the 18S rRNA gene set forth in SEQ ID NO:37 in the 18S rRNA gene or 18S rRNA of a bacterial species are analyzed include those listed in Table 9.
[0361] 5. Application of the method of the present invention The methods of the invention are useful for classifying and / or identifying bacteria, yeast organisms, or mold fungi in a sample, such as a sample from a subject, or an environmental sample, such as a soil or water sample, or a sample taken from an apparatus or device (e.g., medical or surgical equipment) or a work surface. Such classification or identification can then be used to determine a course of treatment to remove, eradicate, or reduce the number of bacteria, yeast organisms, or mold fungi. Any two or more of the methods of the invention may be combined. For example, nucleic acid from a sample can be analyzed for the presence of SNPs in the 16S rRNA gene using the methods of the invention. This can be done to determine whether gram-positive or gram-negative bacteria are present in the sample. The bacteria can be further grouped, or the identity of the bacteria can be determined or narrowed down to one of a few possibilities. For example, as will be apparent from the disclosure above, SNPs at positions corresponding to positions 273, 378, 412, 440, 488, 647, and 653 of the 16S rRNA gene shown in SEQ ID NO: 1 can be investigated to classify or further identify bacteria in a sample.
[0362] Clinicians in clinics, emergency rooms, general medical wards and intensive care units are frequently presented with subjects with an infection or suspected infection. Such patients often have non-diagnostic clinical signs of abnormal body temperature, increased heart and respiratory rates, and abnormal white blood cell counts. The clinician must determine whether the patient has an infection, the severity of the infection, whether to admit the patient to the hospital (if not already admitted), the source of the infection, whether to use an antibiotic, and if so, the type, route and dose of antibiotic. The presence of infection in a patient is most commonly investigated by taking a sample from the patient and growing the organism in culture medium. Once the organism has grown, it can be identified by Gram staining. However, in many infected patients (>50), it is not possible to culture the organism. In the absence of an identified organism, the clinician must rely on clinical judgment and the use of broad-spectrum antibiotics, which are often combined. Indiscriminate use of broad-spectrum antibiotics without knowledge of the identity or susceptibility of the pathogenic organism leads to the development of antibiotic resistance in patients, overuse of antibiotics and potential toxic side effects. Blood culture is a highly sensitive method (1-100 cfu / mL), but only if the blood sample contains viable organisms, which is not always the case.
[0363] Thus, the methods of the present invention are particularly useful in helping clinicians determine whether a subject has an infection and, if so, the appropriate course of treatment based on the classification of the bacterial, yeast organism or mold causing the infection.
[0364] Additionally, the methods of the present invention facilitate the identification of Gram-positive and Gram-negative organisms within hours of drawing whole blood from a subject. The methods of the present invention can also be performed in an efficient time such that results are available to the clinician within hours rather than days. Such attributes allow the clinician to sensitively detect the presence of bacteria, yeast organisms or mold fungi and make informed decisions about treatment (e.g., use of Gram-specific antibiotics, or further grouping or identification of the bacteria). These improvements can result in reduced numbers of patients hospitalized unnecessarily, sensitive detection of bacteria, yeast organisms and mold fungi, severity of infection (and other factors) investigated after challenge, reduced use of broad-spectrum antibiotics / medicines, reduced patient time under broad-spectrum antibiotics, reduced toxicity from antibiotics / medicines, reduced development of resistance to medicines (especially antibiotic resistance).
[0365] The present invention also extends to the diagnosis of bacterial, yeast or fungal infection in a subject, and the management of infection after positive diagnosis.The method of analyzing one or more SNPs in 16S rRNA or 18S rRNA described herein can be used to determine whether a subject has bacterial, yeast or fungal infection, and / or to identify the group or species of bacteria, yeast or fungus in a sample.The method described herein can further be used to classify bacteria as Gram-positive or Gram-negative.
[0366] 5.1 Management and Therapy Based on the results of the methods of the invention, the subject can be appropriately managed and therapy administered, if necessary. For example, management of a bacterial infection can include administration of a therapeutic agent, such as, for example, a course of a therapeutically effective antibiotic.
[0367] In general, the therapeutic agent is administered in the form of a pharmaceutical (or veterinary, if the subject is a non-human subject) composition together with a pharmaceutically acceptable carrier, and in an amount effective to achieve their intended purpose. The dose of the active compound administered to the subject should be sufficient to achieve a beneficial response in the subject over time, such as reduction or alleviation of symptoms of infection and / or reduction or excretion of bacteria from the subject. The amount of the pharmaceutically active compound(s) to be administered may depend on the subject being treated, for example, its age, sex, weight and general health condition. In this regard, the exact amount of the active compound(s) for administration will depend on the judgment of the practitioner. In determining the effective amount of the active compound(s) to be administered in the treatment or prevention of bacterial infection, the practitioner can evaluate the severity of the infection and the severity of any symptoms associated with the infection, including inflammation, blood pressure abnormalities, rapid heartbeat, rapid breathing, fever, chills, vomiting, diarrhea, skin rash, headache, confusion, muscle pain and seizures. In any event, one of ordinary skill in the art can readily determine suitable dosages of therapeutic agents and suitable treatment regimens without undue experimentation.
[0368] Therapeutic agents can be administered in conjunction with supportive (symptomatic) therapies to increase oxygenation to vital organs, increase blood flow to vital organs, and / or reduce inflammatory responses. Illustrative examples of such supportive therapies include nonsteroidal anti-inflammatory drugs (NSAIDs), intravenous saline, and oxygen.
[0369] Aspects of the present invention are further described in the following sections: [Section 1] 1. A method for identifying, partially identifying, or classifying at least one bacterium, yeast organism, or filamentous fungus in a sample, comprising analyzing at least a portion of a bacterial 16S rRNA gene or gene product from said sample, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus from said sample, for the presence or absence of at least one single nucleotide polymorphism (SNP); the at least one SNP in the at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of the 16S rRNA gene set forth in SEQ ID NO:1; The method, wherein said at least one bacterium, yeast organism, or filamentous fungus in said sample is identified, partially identified, or classified based on the presence or absence of said at least one SNP. [Section 2] 1. A method of identifying, partially identifying, classifying or diagnosing a bacterial, yeast organism or filamentous fungal infection in a subject, comprising analyzing in a sample from the subject for the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus; the at least one SNP in the at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of the 16S rRNA gene set forth in SEQ ID NO:1; The method, wherein the presence or absence of the at least one SNP in the at least a portion of the 16S rRNA gene or gene product, or the at least a portion of the 18S rRNA gene or gene product, is used to identify, partially identify, classify or diagnose an infection of the bacterial, yeast organism or filamentous fungus in the subject. [Section 3] 1. A method of treating a subject having a bacterial, yeast organism, or mold infection, comprising: identifying, partially identifying, classifying or diagnosing said bacterial, yeast organism or fungal infection in said subject by the method according to claim 2 above to identify, partially identify, classify or diagnose said bacterial, yeast organism or fungal infection in said subject; administering to said subject a treatment or therapeutic agent for treating said bacterial, yeast organism or fungal infection in said subject. The method includes: [Section 4] 4. The method according to any one of items 1 to 3, wherein the sample is a biological sample comprising sputum, blood, cerebrospinal fluid or urine. [Section 5] The method according to any one of claims 1 to 4, wherein the analyzing step comprises determining the presence or absence of the at least one SNP using high-resolution melting analysis, 5' nuclease digestion, molecular beacons, oligonucleotide ligation, microarrays, restriction fragment length polymorphism, antibody detection methods, direct sequencing or any combination thereof. [Section 6] 6. The method of any one of paragraphs 1 to 5, further comprising determining whether the at least one bacteria, yeast organism or filamentous fungus is resistant to a treatment agent. [Section 7] 1. A method for identifying at least one bacterium in a sample, comprising analyzing nucleic acid from the sample for at least one SNP located in a bacterial 16S rRNA gene at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647 and 653 of the 16S rRNA gene as set forth in SEQ ID NO:1, wherein the at least one bacterium is identified based on the presence of the at least one SNP. [Section 8] 7. The method according to any one of claims 1 to 6, wherein the at least one SNP in the at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 737, 755, 762 and 776 of the 16S rRNA gene as shown in SEQ ID NO:1. [Section 9] The method according to any one of claims 1 to 6, wherein the at least one SNP in the at least a portion of the 18S rRNA gene or gene product of the yeast organism or filamentous fungus is located at a position corresponding to at least one of positions 343, 371, 388, 416 and 467 of the 18S rRNA gene or gene product as set forth in SEQ ID NO: 37. [Section 10] at least a portion of a bacterial 16S rRNA gene or gene product from said sample, or at least a portion of a yeast organism or filamentous fungal 18S rRNA gene or gene product from said sample; single nucleotide polymorphisms at positions within said at least a portion of said bacterial 16S rRNA gene or gene product that correspond to at least four of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of said 16S rRNA gene as set forth in SEQ ID NO:1; or single nucleotide polymorphisms at positions corresponding to positions 343, 371, 388, 416 and 467 of the 18S rRNA gene as set forth in SEQ ID NO:37 within said at least a portion of an 18S rRNA gene or gene product of said yeast organism or filamentous fungus; 7. The method according to any one of claims 1 to 6, comprising analyzing for the presence or absence of: [Section 11] The bacteria or the bacterial infection is Acinetobacter calcoaceticus;Enterobacter aerogenes;Enterobacter cloacae;Enterococcus faecalis;Enterococcus faecium;Escherichia coli;Klebsiella pneumoniae;Proteus mirabilis;Pseudomonas aeruginosa;Serratia marcescens;Staphylococcus aureus;Staphylococcus epidermidis;Streptococcus agalactiae;Streptococcus pneumoniae;Streptococcus pyogenes;Listeria monocytogenes;Clostridium perfringens;Corynebacterium jeikeium;Bacteroides fragilis;Neisseria meningitides;Haemophilus influenzae;Salmonella sp. and Staphylococcus 7. The method according to any one of items 1 to 6, wherein the method is caused by at least one selected from the group consisting of: Bacillus subtilis, Bacillus epidermidis, or Bacillus subtilis. [Section 12] 7. The method according to any one of claims 1 to 6, wherein the bacterium or the bacterial infection is at least one selected from the group consisting of Bacillus anthracis, Clostridium botulinum, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei, or is caused by it. [Section 13] 7. The method according to any one of claims 1 to 6, wherein the yeast organism or filamentous fungus is at least one selected from the group consisting of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Fusarium sp., Aspergillus fumigatus and Cryptococcus neoformans. [Section 14] 1. A method of identifying, partially identifying, classifying or diagnosing an infectious disease in a subject, wherein the infectious disease is an infection of a bacteria, a yeast organism or a filamentous fungus, the method comprising testing a biological sample obtained from the subject for a characteristic of at least one bacterial 16S rRNA gene or gene product or a portion thereof, or at least one yeast organism or filamentous fungus 18S rRNA gene or gene product or a portion thereof, the testing comprising detecting at least one single nucleotide polymorphism (SNP) in the at least one bacterial 16S rRNA gene or gene product or a portion thereof, or at least one yeast organism or filamentous fungus 18S rRNA gene or gene product or a portion thereof; the at least one SNP in the bacterial 16S rRNA gene or gene product or portion thereof is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of the 16S rRNA gene set forth in SEQ ID NO:1; The method, wherein said at least one bacteria, yeast organism or filamentous fungus in said sample is identified, partially identified, classified or diagnosed based on the presence or absence of said at least one SNP. [Section 15] At least one isolated probe, tool or reagent capable of identifying, partially identifying or classifying at least one bacterium, yeast organism or filamentous fungus in a sample, capable of binding, detecting or identifying the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus; The at least one SNP in the at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762 and 776 of the 16S rRNA gene as set forth in SEQ ID NO:1. [Section 16] At least one isolated probe, tool or reagent according to item 15 above, comprising an oligonucleotide having a nucleotide sequence set forth in at least one of SEQ ID NOs: 16 to 35 and 53 to 57. [Section 17] 1. A method for identifying, partially identifying, or classifying at least one bacterium, yeast organism, or filamentous fungus in a sample, comprising: combining at least one isolated probe, tool or reagent according to claim 15 or claim 16 with said sample; and identifying, partially identifying, or classifying at least one bacterium, yeast organism, or filamentous fungus based on the presence or absence of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of the yeast organism or filamentous fungus; The method of claim 1, wherein the at least one SNP in the at least a portion of the bacterial 16S rRNA gene or gene product is at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of the 16S rRNA gene as set forth in SEQ ID NO:1. [Section 18] 17. An array comprising more than one of the isolated probes, tools or reagents according to paragraph 15 or paragraph 16. [Section 19] A biochip comprising a solid substrate and at least one isolated probe, tool or reagent according to paragraph 15 or paragraph 16 above. [Section 20] A kit or assay for classifying or identifying at least one bacteria or at least one yeast organism or filamentous fungus in a sample, comprising at least one probe, tool or reagent described in paragraph 15 or paragraph 16 above; an array described in paragraph 18 above; and / or a biochip described in paragraph 19 above. [Section 21] At least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of an 18S rRNA gene or gene product of a yeast organism or filamentous fungus, for use as an indicator for classifying, identifying, or partially identifying at least one bacterium, yeast organism, or filamentous fungus in a sample, The at least one SNP in the at least a portion of the bacterial 16S rRNA gene or gene product is a single nucleotide polymorphism (SNP) at a position corresponding to at least one of positions 273, 378, 412, 440, 488, 647, 653, 737, 755, 762, and 776 of the 16S rRNA gene as set forth in SEQ ID NO:1. [Section 22] Use of at least one single nucleotide polymorphism (SNP) in at least a portion of a bacterial 16S rRNA gene or gene product, or at least a portion of a yeast organism or filamentous fungus 18S rRNA gene or gene product, as described in paragraph 1 above, or at least one isolated probe, tool or reagent as described in paragraph 15 or paragraph 16 above, in identifying, partially identifying or classifying at least one bacterium, yeast organism or filamentous fungus in a sample, wherein the at least one bacterium, yeast organism or filamentous fungus is identified, partially identified or classified based on the presence or absence of at least one SNP in at least a portion of the 16S rRNA gene or gene product, or at least a portion of the 18S rRNA gene or gene product from the sample. References throughout this specification to "one embodiment" or "an embodiment" mean that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the invention. Thus, appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more combinations.
[0370] In accordance with the statute, the invention has been described in terms that are more or less specific to structural or methodological features. It is to be understood that the invention is not limited to the specific features shown or described, since the means described herein include preferred modes of carrying out the invention. The invention is therefore claimed in any of its forms or modified forms within the proper scope of the appended claims (if any) as appropriately interpreted by those skilled in the art.
[0371] The disclosures of all patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety.
[0372] In order that the present invention may be readily understood and practiced, certain preferred embodiments will now be described by way of the following non-limiting examples. EXAMPLES
[0373] The objective of this study was to distinguish 15 of the most prevalent bacterial species frequently isolated from patients diagnosed with sepsis using the 16S rRNA SNP-HRM assay of the present invention.
[0374] Experimental procedure In total, the following 15 bacterial species were tested: Acinetobacter calcoaceticus;Enterobacter aerogenes;Enterobacter cloacae;Enterococcus faecalis;Enterococcus faecium;Escherichia coli;Klebsiella pneumoniae;Proteus mirabilis;Pseudomonas aeruginosa;Serratia marcescens;Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus pneumoniae and Streptococcus pyogenes.
[0375] These bacterial species were cultured in brain heart infusion broth overnight at 37°C, and then genomic DNA was extracted from each isolate using the QIAgen DNeasy blood and tissue kit (Qiagen, Australia).
[0376] 16S rDNA-SNP primers (SEQ ID NO: 16-35, produced by Sigma Aldrich, Australia) were designed to amplify a region encompassing seven SNPs, named as follows: SNP273, SNP378, SNP412, SNP440, SNP488, SNP647 and SNP653 of the 16S rRNA gene shown in SEQ ID NO: 1. The sizes of the PCR products ranged from 79 bp to 96 bp.
[0377] Real-time PCR and subsequent HRM analysis were used to differentiate between 15 bacterial species. The real-time PCR HRM method was as follows: 1 μl of extracted DNA (1–3 ng) was added to 19 μl of reaction mastermix containing 10 μl of 2× SYBR green PCR Mastermix (Invitrogen, Australia) and 8 pmol of each primer. The temperature cycles for these reactions were as follows: 50°C for 2 min, 95°C for 2 min, followed by 40 cycles of 95°C for 15 s, 52°C for 20 s and 72°C for 35 s, hold at 72°C for 2 min, hold at 50°C for 20 s, HRM: ramp from 65°C to 95°C with 0.05°C increments (Rotor-Gene 6000, Qiagen, Australia).
[0378] Rotor-Gene 6000 software (version 1.7.34 or 1.7.87) was used to analyze the HRM data in multiple ways. Normalized raw melting curves show the decrease in fluorescence versus increasing temperature, and difference curves show a user-defined curve as the baseline (i.e., x-axis) versus the other normalized curve. Criteria for calling melting curves "same" or "different" using difference graphs have been previously developed and published by the inventors and collaborators (see, e.g., Stephens, AJ, et al. 2008; Merchant-Patel, S., et al. 2010).
[0379] There are two ways samples can be distinguished on the HRM curve graph. The shape of the melting curve is Curve shape Show details of Curve Shift indicates the thermal (temperature) offset of a curve from another curve.
[0380] As generally described above, the software allows for HRM melting curve analysis, either as normalized melting curves or as difference curves. Normalized curve analysis allows for comparison of all HRM curves at the same starting and ending fluorescent signal levels to aid interpretation and analysis. Difference curve analysis shows the differences between the melting curves of each sample and a given control.
[0381] In this study, both shape and shift approaches were used to identify the HRM curves for each bacterial species tested. To determine the melting point shift for each respective bacterial species, a melting point difference of 0.2°C was considered as a significant difference between the melting curves of each bacterial species.
[0382] To determine shape differences between bacterial species, difference curve analysis was used. Differences in width of >5 normalized fluorescence units indicate that the melting curves of the different bacterial species differ from the comparator species. Thus, these differences in curve shape indicate differences in the DNA sequence of each respective bacterial species.
[0383] result Figures 2-11 show the normalized and differential melting curve graphs used to distinguish the 15 bacterial species tested in this example.
[0384] Each of the 15 bacterial species was assigned a species-specific genotype in the HRM analysis settings of the Rotor-Gene 6000 software (version 1.7.34 or 1.7.87). For comparison of bacterial species differentiation curves, Escherichia coli was used as the "calibrator" or "reference" (denoted by "0" on the Y-axis of the graph shown in Figure 3). As shown in Figure 3, all of the other 14 bacterial species showed curves that were significantly different from the "0" line of Escherichia coli. Another example of species differentiation is shown in Figure 5, where Staphylococcus aureus was selected as the "calibrator" or "reference" (denoted by "0" on the Y-axis), and Staphylococcus epidermidis has a completely separate curve as shown.
[0385] The melting curve specificities of bacteria in urine and plasma are shown in Table 11.
[0386] [Table 11]
[0387] Consideration This example demonstrates the utility of applying only seven highly discriminatory SNPs to differentiate between 15 different bacterial species known to cause life-threatening diseases such as sepsis. The results also show that the method of the present invention is highly specific and rapid, both of which are important prerequisites for DNA diagnostic assays. The method accurately determines whether two isolates are the same or different based on the DNA melting curves of PCR products encompassing the highly discriminatory SNPs. Interrogating these genetic targets means that the approach is particularly amenable to adaptation to emerging technologies such as "lab-on-a-chip" devices and dedicated fully automated real-time PCR instruments. Combined with rapidly advancing innovations in microfluidics, the method of the present invention is suitable for conversion to devices suitable for "point-of-care" diagnostics. EXAMPLES
[0388] To demonstrate the utility of the present invention, 200 blood culture positive patient samples were investigated by both standard clinical microbiology and the methods of the present invention.
[0389] Standard clinical microbiology testing was performed in the laboratory with routine blood culture procedures utilizing the BacTAlert system followed by the MALDI biotyping method for bacterial species identification. This involved placing the BacTAlert blood culture bottles into an automated continuous monitoring incubation and incubating for 5-7 days. Once the blood culture bottles were found to be positive (minimum 12 hours of incubation), the bottles were removed from the BacTAlert instrument and an aliquot of growth medium was removed and subcultured onto bacterial culture agar plates. The agar plates are incubated at 37°C for at least 4 hours or until visible growth appears. A single bacterial colony is then placed onto the target plate and matrix solution is added. The plate is inserted into the biotyping instrument and a MALDI-TOF spectrum is generated by the software. This spectrum is compared to a reference library to provide the bacterial identification. The total time for this method is approximately 16-18 hours. Standard clinical microbiology testing was performed by Pathology Queensland.
[0390] In the method used according to the invention, blood culture fluid (1 mL) was collected from 100 negative blood culture samples after 5 days of incubation in a BacTAlert blood culture machine and stored at 4° C. until extraction. Blood culture fluid (1 mL) was also collected from 200 positive blood culture samples by staff from the Diagnostic Microbiology Department at Pathology Queensland and stored at 4° C. until DNA extraction. Microbial DNA was isolated from all samples (negative and positive blood cultures) using the MolYsis™ Complete 5 Kit (Molzym Life Science, Germany), which allows removal of host DNA, pathogen enrichment and DNA extraction from 1 mL samples.
[0391] A total of 300 DNA extracts were subjected to testing using a real-time PCR format as follows: 1 microliter of extracted DNA (1-3 ng) was added to 19 μl of reaction mastermix containing 10 μl of 2× SYBR green PCR Mastermix (Life Technologies, Australia) and 8 pmol of each primer. Temperature cycles for these reactions were as follows: 50°C for 2 min, 95°C for 2 min, followed by 40 cycles of 95°C for 15 s, 52°C for 20 s and 72°C for 35 s, hold at 72°C for 2 min, hold at 50°C for 20 s, HRM:HRM:65°C to 95°C ramp with 0.05°C increments (RotorGeneQ, Qiagen, Australia). All samples were run in duplicate, including appropriate controls (no template (NTC) and positive controls consisting of bacterial reference DNA for each bacterial species tested). Time to result was recorded to be ±3.5 hours.
[0392] Results were tabulated and linked to blood culture microbiology results obtained from Pathology Queensland at the end of the study.
[0393] result The results of the study are shown in Table 12.
[0394] [Table 12]
[0395] Advantageously, the method of the present invention was able to obtain a specificity of 99% when compared to clinical microbiology results (however, for two samples where clinical microbiology and the method of the present invention gave different results, it is unclear which method gave the incorrect result). The method of the present invention was able to obtain results within about 3.5 hours and with minimal processing of the patient sample. In contrast, clinical microbiology results required more extensive processing of the patient sample and took about 16-18 hours to obtain.
[0396] References Anderson & Borreson, 1995, Diagnostic Molecular Pathology, 4: 203-211. Andersson, P., et al., 2009, Antimicrob. Agents Chemother. 53:2679-2683. Ausubel et al., Current Protocols in Molecular Biology (John Wiley & Sons, Inc. 1994-1998. Bullock, G. R. et al., 1985, Techniques in Immunocytochemistry, Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985). Chard, T., 1986, An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986) Chee, et al., 1996, Science 274: 610-613. Chumanov, G. "Surface Enhanced Raman Scattering (SERS) for Discovering and Scoring Single Based Differences in DNA" Proc. Volume SPIE, 3608 (1999). Cotton, et al., 1988, Proc. Natl. Acad. Sci. USA, 85:4397. Cronin, et al., 1996, Human Mut. 7: 244-255. De Risi et al, 1996, Nat. Genet. 14: 457-460. DeRisi et al., 1997, Science 270:680-686. Deveraux et al., 1984, Nucleic Acids Research 12, 387-395. Drmanac and Drmanac, 1999, Methods Enzymol. 303: 165-178 Drmanac et al., 1993, Science 260: 1649-1652. Drmanac et al., 1998, Nature Biotech. 16: 54-58. Gibbs et al., 1989, Nucleic Acids Research, 17: 2347. Gibbs, R. A. and Caskey, T., 1987, Science, 236:303-305. Ginot, 1997, Human Mutation 10:1-10. Hacia et al., 1996, Nat. Genet. 14: 441-447. Jobs et al., 2003, Genome Res 13: 916-924. Karlowsky, J.A., et al. (2004) Ann Clin Microbiol Antimicrob. 10;3:7. Kim S. & Misra A. 2007, Ann Rev Biomed Eng. 9:289-320. Kneipp, K, 1997, Physical Review Letters, 78(9):1667-1670. Komher, J. S. et al., 1989, Nucl. Acids. Res. 17: 7779-7784. Kumar, D. et al., 2006, Genet. Mol. Biol, 29(2):287-289. Kuppuswamy, M. N. et al., 1991 Proc. Natl. Acad. Sci. (U.S.A.) 88:1143-1147. Levy et al., 2003, Critical Care Medicine, 31:1250-1256. Liu et al, 1996, J. Am. Chem. Soc. 118: 1587-1594. Lockhart et al., 1996, Nature Biotechnol. 14:1675-1680. Lu, A. L. and Hsu, I. C., 1992, Genomics, 14(2):249-255. Lyamichev, V. et al., 1999, Nat Biotechnol, 17: 292-296. Maxam, A. M., et al., 1977, Proc. Natl. Acad. Sci. (U.S.A.) 74:560. Merchant-Patel, S., et al., 2008, Int. J. Food Microbiol., 128:304-308. Merchant-Patel, S., Blackall, P.J., Templeton, J., Price, E.P., Tong, S.Y.C., Huygens, F., and Giffard, P.M., 2010, Applied and Environmental Microbiology., 76(2):493-499. Meyers, R. M., et al., 1985 Science, 230:1242-1246. Milosavljevic et al., 1996, Genomics, 37: 77-86. Modrich, 1991, Ann. Rev. Genet., 25: 229-253. Nagamine, C. M. et al., 1989, Am. J. Hum. Genet, 45:337-339. Newton et al., 1989, Nucl. Acids Res. 17: 2503-2516. Novack et al., 1986, Proc. Natl. Acad. Sci. USA, 83:586. Nyren, P., et al., 1993 Anal. Biochem. 208: 171-175. Orita, M. et al., 1989, Proc Natl Acad Sci USA, 86:2766. Prezant, T. R., et al., 1992 Hum. Mutat. 1: 159-164. Price, E.P., et al., 2007, Appln. Environ. Microbiol, 72:7793-7803. Prince, J. A., et al., 2001 Genome Res, 11(1):152-162. Protocols for Oligonucleotides and Analogues; Synthesis and Properties", Methods in Molecular Biology Series, Volume 20, Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7, 1993. Ramsay, 1998, Nature Biotech. 16: 40-44. Reinhart et al., 2012, Clinical Microbiology Reviews 25(4): 609-634. Saleeba, J. A., et al., 1992 Huma. Mutat, 1:63-69 Salimullah, et al., 2005, Cellular and Mol. Biol. Letts, 10: 237-245 Sapolsky and Lishutz, 1996, Genomics 33: 445-456 Schena et al., 1995, Science 270: 467. Shalon, et al., 1996, Genome Res. 6: 639. Sheffield et al., 1989, Proc. Natl. Acad. Sci. USA 86: 232-236 Shenk et al., 1975, Proc. Natl. Acad. Sci. USA, 72:989. Shoemaker et al., 1996, Nat. Genet. 14: 450-456. Smith-Sorenson et al., 1993, Human Mutation 2:274-285. Sokolov, B. P., 1990, Nucl. Acids Res. 18: 3671. Sooknanan et al., 1994, Biotechniques 17:1077-1080. Stephens, A.J., Inman-Bamber, J., Giffard, P.M., and Huygens, F., 2008, Clinical Chemistry. 54(2):432-436. Syvaenen, A. C, et al., 1990 Genomics, 8: 684-692. Syvaenen, A. C, et al., 1993, Amer. J. Hum. Genet. 52: 46-59. Syvaenen, A. C., 2001, Nat. Rev. Genet. 2, 930-942. Thelwell et al., 2000 Nucleic Acid Res. 28(19): 3752-3761. Tijssen, P., 1985, Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands. Tyagi et al., 1996, Proc. Natl. Acad. Sci. USA 93:5395-5400. Tyagi, S and Kramer, F. R., 1996, Nat.Biotechnol, 14: 303-308 Ugozzoli, L., et al., 1992, GATA, 9: 107-112. Wartell et al., 1990 Nucl. Acids Res. 18:2699-2705 Weisburg WG, et al., (1991) J Bacteriol. 173 (2): 697-703. Wodicka et al, 1997, Nat. Biotech. 15: 1-15. Xiao and Kwok, 2003, Genome Research, 13(5): 932-939. Yershov et al., 1996, Genetics 93: 4913-4918.
Claims
1. 1. A method of identifying or classifying at least one bacterium selected from the group consisting of Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae, and Burkholderia pseudomallei in a sample, comprising analyzing at least a portion of a bacterial 16S rRNA gene or gene product from the sample for the presence or absence of single nucleotide polymorphisms (SNPs) therein at positions corresponding to positions 737, 755, 762, and 776 of the 16S rRNA gene as set forth in SEQ ID NO:1; wherein identifying bacteria from among said bacteria based on the presence or absence of at least one said SNP, when there is a T at position 737, an A at position 755, a C at position 762, and a G at position 776, the bacterium is Bacillus anthracis; when there is a T at position 737, a G at position 755, a C at position 762, and a T at position 776, the bacterium is Clostridium botulinum type A or Clostridium botulinum type B; when there is a T at position 737, an A at position 755, a T at position 762, and a T at position 776, the bacterium is Clostridium botulinum type C; when there is a C at position 737, an A at position 755, a T at position 762, and a T at position 776, the bacterium is Clostridium botulinum type D; when there is a T at position 737, a G at position 755, a C at position 762, and a G at position 776, the bacterium is Clostridium botulinum type G; when there is a C at position 737, a G at position 755, a T at position 762, and a G at position 776, the bacterium is Yersinia pestis; When there is a T at position 737, an A at position 755, a G at position 762, and a G at position 776, the bacterium is Francisella tularensis; When there is a C at position 737, an A at position 755, a T at position 762, and a G at position 776, the bacterium is Vibrio cholerae; When there is a C at position 737, a G at position 755, a C at position 762, and a G at position 776, the bacterium is Burkholderia pseudomallei; method.
2. The method of claim 1, wherein melting curve analysis is used to distinguish species.
3. 3. The method of claim 1 or claim 2, wherein the sample is a biological sample comprising sputum, blood, cerebrospinal fluid or urine.
4. 4. The method of any one of claims 1 to 3, wherein the analyzing step comprises determining the presence or absence of the SNP using high resolution melting analysis, 5' nuclease digestion, molecular beacons, oligonucleotide ligation, microarrays, restriction fragment length polymorphism, antibody detection methods, direct sequencing or any combination thereof.
5. 5. The method of any one of claims 1 to 4, further comprising determining whether the at least one bacterium is resistant to a treatment agent.
6. 2. The method of claim 1, wherein the sample is combined with a panel of isolated probes comprising oligonucleotides comprising the nucleotide sequences set forth in SEQ ID NOs:56 and 57.
7. The method of claim 6 , wherein the panel of isolated probes is comprised in an array or a biochip.
8. 1. A method of aiding in the diagnosis of a bacterial infection or aiding in antibiotic treatment decisions in a subject with at least one bacterium selected from the group consisting of Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae, and Burkholderia pseudomallei, comprising: Identifying or classifying at least one bacterium in a sample taken from the subject by the method of any one of claims 1 to 7; and Providing the results of said identification or classification as an aid to said diagnosis or as an aid to said antibiotic treatment decision. A method comprising:
9. 1. A panel of isolated probes capable of identifying or classifying at least one bacterium selected from the group consisting of Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae, and Burkholderia pseudomallei in a sample, the panel of isolated probes being capable of binding to, detecting, or identifying the presence or absence of single nucleotide polymorphisms (SNPs) at positions in at least a portion of a bacterial 16S rRNA gene or gene product that correspond to positions 737, 755, 762, and 776 of the 16S rRNA gene as set forth in SEQ ID NO:
1.
10. 10. The panel of isolated probes of claim 9, wherein said isolated probes comprise oligonucleotides having the nucleotide sequences set forth in SEQ ID NOs:56 and 57.
11. 11. An array comprising a panel of isolated probes according to claim 9 or claim 10.
12. A biochip comprising a solid substrate and a panel of isolated probes according to claim 9 or claim 10.
13. 13. A kit for classifying or identifying at least one bacterium in a sample, comprising a panel of isolated probes according to claim 9 or claim 10; an array according to claim 11; or a biochip according to claim 12.
Citation Information
Patent Citations
Microbial markers and their use
JP2016520314A
